"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT02387151","Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients","Neptune","Completed","No Results Available","Rejection|Graft Loss","Drug: mesenchymal stromal cells","biopsy proven acute rejection / graft loss|Comparison of fibrosis by quantitative Sirius Red scoring|Serious adverse events|Renal function measured by cGFR (MDRD formula) and iohexol clearance|CMV, BK infection (viremia, disease and syndrome; and subtypes of BK viremia) and other opportunistic infections|Development of de novo donor specific antibodies (DSA) and immunological responses","Leiden University Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL4724400013|2013-005407-14","March 2015","November 2018","November 2018","March 12, 2015",,"July 2, 2019","Leiden University Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT02387151"
2,"NCT04447833","Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome","ARDS-MSC-205","Active, not recruiting","No Results Available","ARDS, Human|COVID","Drug: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205","The incidence of pre-specified treatment related adverse events of interest (TRAEIs).|Safety; All-cause mortality|Changes in Leucocytes|Changes in Trombocytes|Changes in plasma concentration of C-reactive protein (CRP)|Changes in plasma concentration of Prothrombin complex (PK)|Changes in plasma concentration of Creatinine|Changes in plasma concentration of Aspartate amino transferase (ASAT)|Changes in plasma concentration of Alanine amino transferase (ALAT)|Changes in plasma concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP)|Changes in Blood pressure|Changes in Body temperature|Efficacy; Changes in pulmonary compliance|Efficacy; Changes in driving pressure (Plateau pressure- PEEP)|Efficacy; Changes in oxygenation (PaO2/FiO2)|Efficacy; Duration of ventilator support|Efficacy; Pulmonary bilateral infiltrates|Efficacy; Sequential Organ Failure Assessment (SOFA) score|Efficacy; Hospital stay|Lung function|Lung fibrosis|Six minutes walk test|Changes in Quality of life|Blood biomarkers|Sensitisation test","Uppsala University|Uppsala University Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-02238","June 17, 2020","January 30, 2021","June 30, 2025","June 25, 2020",,"March 4, 2021","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT04447833"
3,"NCT03268603","Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)",,"Recruiting","No Results Available","ALS|Amyotrophic Lateral Sclerosis","Drug: Autologous Adipose-derived Mesenchymal Stromal Cells","Number of Adverse Events|Change in slope of ALS Functional Rating Scale - Revised (ALSFRS-R)","Mayo Clinic|State of Minnesota Regenerative Medicine Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-008008|UL1TR000135","October 10, 2017","December 2022","December 2022","August 31, 2017",,"February 16, 2022","Mayo Clinic, Scottsdale, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03268603"
4,"NCT01090817","An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease",,"Completed","No Results Available","Crohn Disease","Drug: Mesenchymal stromal cells (MSC) for infusion","Clinical response to MSC: Reduction of Crohn's disease Activity score by 100 points or more at six weeks post start of therapy|Incidence of infusional toxicity|Induction of remission|Improved quality of life|Endoscopic improvement.","R.P.Herrmann|The Queen Elizabeth Hospital|Concord Hospital|Sir Charles Gairdner Hospital|The Alfred|Royal Perth Hospital","All","18 Years to 55 Years   (Adult)","Phase 2","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC2009/123|CTN2010/0098","January 2010","June 2014","June 2015","March 23, 2010",,"June 9, 2015","Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT01090817"
5,"NCT02012153","Mesenchymal Stromal Cells in Kidney Transplant Recipients",,"Recruiting","No Results Available","Kidney Transplant Rejection","Biological: Mesenchymal Stromal Cells","Circulating naïve and memory T cell count (CD45RA/CD45RO) (flow cytometry analysis).|T-cell function by ELISPOT assay in mixed lymphocyte reaction.|Number of adverse events.|Circulating regulatory T cell count.|Urinary FOXP3 mRNA expression evaluated by real time quantitative PCR.","Mario Negri Institute for Pharmacological Research|A.O. Ospedale Papa Giovanni XXIII","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-Tx tolerance|2013-003221-29","December 2013","December 2022","March 2023","December 16, 2013",,"November 26, 2021","U.O. Nefrologia e Dialisi, Bergamo, Italy",,"https://ClinicalTrials.gov/show/NCT02012153"
6,"NCT02150551","Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease",,"Completed","No Results Available","Inflammatory Bowel Diseases","Biological: Allogeneic bone marrow-derived mesenchymal stromal cells","Number of subjects who experience serious adverse events, adverse events, and/or early treatment discontinuations.|Proportion of patients with clinical response|Number of subjects demonstrating an improvement of laboratory tests reflecting systemic inflammation.|Number of subjects with endoscopic healing after treatment.","Catherine Bollard|Children's National Research Institute","All","12 Years to 22 Years   (Child, Adult)","Phase 1","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STOMP","September 2015","September 27, 2019","September 27, 2019","May 30, 2014",,"July 14, 2020","Children's National Medical Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT02150551"
7,"NCT05286255","Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias","SAMPSON-1","Recruiting","No Results Available","COVID-19 Pneumonia|Viral Pneumonia","Biological: Allogeneic Mesenchymal Stromal Cells","Clinical deterioration|Serious Adverse Events|ICU transfer|Respiratory support|Hospital mortality and length of stay|Ventilator free days|28 day mortality","Medical University of South Carolina|Pandorum International, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","115966","May 4, 2022","May 4, 2023","May 4, 2023","March 18, 2022",,"May 10, 2022","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT05286255"
8,"NCT02814864","Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy","PRISME","Recruiting","No Results Available","Pelvic Radiation Therapy|Radiation-induced Hemorrhagic Cystitis","Drug: Mesenchymal Stromal Cell (MSC) injections","Decrease of one grade on the LENT SOMA|The effect of treatment on analgesic drug consumption (analgesic, opiates).|The effect of treatment on quality of life with SF36 questionnaire|The effect of treatment on quality of life with HADS questionnaire|The effect of treatment on pain|Frequency of diarrhea","Assistance Publique - Hôpitaux de Paris","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P130935|2014-001462-99","April 14, 2021","April 2022","April 2022","June 28, 2016",,"August 3, 2021","Hématologie et thérapie cellulaire, Hôpital Saint Antoine, Paris, France",,"https://ClinicalTrials.gov/show/NCT02814864"
9,"NCT03818854","Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome","STAT","Recruiting","No Results Available","Respiratory Distress Syndrome, Adult","Biological: Human Mesenchymal Stromal Cells|Biological: Cell Reconstitution Media","Change in oxygenation index (OI)|Acute Lung Injury Score (LIS)|Pulmonary Dead Space Fraction|Chest radiograph assessment of pulmonary edema (RALE score)|Ventilator free-days|Duration of assisted ventilation over 28 days|Percentage of patients achieving pressure support ventilation for 2 hours|Occurrence of Infection|Sequential Organ Failure Assessment (SOFA) over 7 days|All-cause hospital mortality|Glasgow Outcome Score (GCS)|Percentage of patients occurred any thromboembolic events|Plasma angiopoietin-2|Plasma Receptor for Advanced Glycation Endproducts (RAGE)|Plasma interleukin-6|Plasma interleukin-8|Plasma Soluble tumor necrosis factor 1 (sTNF-1)|Plasma protein C|Plasma lipoxin A4|Plasma Resolvin D1|Plasma angiopoietin-1|Plasma keratinocyte growth factor (KGF)|Urine microalbumin|Total protein in min-bronchoalveolar lavage (mBAL)|Tolerability of the hMSCs - incidence of pre-specified infusion-associated events and unexpected severe adverse events","Michael A. Matthay|United States Department of Defense|Harborview Injury Prevention and Research Center|Oregon Health and Science University|Vanderbilt University Medical Center|The University of Texas Health Science Center, Houston|University of Minnesota|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UCSF-hMSC-ARDS-P1P2-12","November 26, 2019","July 1, 2023","July 1, 2024","January 28, 2019",,"September 14, 2022","University of California Davis Medical Center, Sacramento, California, United States|Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Memorial Hermann Hospital - Texas Medical Center, Houston, Texas, United States|Harborview Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03818854"
10,"NCT04445454","Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection",,"Recruiting","No Results Available","Coronavirus Infection","Biological: Mesenchymal stromal cells","To evaluate the safety of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia|To evaluate the efficacy of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia|To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)","University of Liege","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TJT2012","June 12, 2020","September 30, 2024","September 30, 2024","June 24, 2020",,"September 21, 2022","CHU de Liège, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT04445454"
11,"NCT02097641","Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)","START","Completed","Has Results","Respiratory Distress Syndrome, Adult","Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells|Biological: Plasma-Lyte A","Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion|Numbers of Patients Occurred Any Cardiac Arrest or Death Within 24 Hours of Study Infusion|Numbers of Patients Occurred Any Unexpected Severe Adverse Events (Including All-cause Deaths)|PaO2:FiO2 Change From Baseline to Day 3|Lung Injury Score From Baseline to Day 3|Oxygenation Index Change From Baseline to Day 2|SOFA Score Change From Baseline to Day 3|Number of Patients Death to Day 28|Mortality to Day 60|Number of Ventilator-free Days to Day 28|Non-pulmonary Organ-failure-free Days to Day 28|Angiopoietin 2 Change From Baseline to 6 h|Angiopoietin 2 Change From Baseline to 24 h|Interleukin 6 Change From Baseline to 6 h|Interleukin 6 Change From Baseline to 24 h|Interleukin 8 Change From Baseline to 6 h|Interleukin 8 Change From Baseline to 24 h|RAGE Change From Baseline to 6 h|RAGE Change From Baseline to 24 h","Michael A. Matthay|National Heart, Lung, and Blood Institute (NHLBI)|Massachusetts General Hospital|Stanford University|University of Pittsburgh|University of Minnesota|Ohio State University|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UCSF-hMSC-ARDS-P2|1U01HL108713-01","March 15, 2014","March 9, 2017","February 9, 2018","March 27, 2014","April 10, 2019","April 10, 2019","University of California San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Minnesota Medical Center, Saint Paul, Minnesota, United States|Ohio State University, Columbus, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02097641/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02097641"
12,"NCT04345601","Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)",,"Recruiting","No Results Available","Sars-CoV2|Acute Respiratory Distress Syndrome|COVID-19","Biological: Mesenchymal Stromal Cells|Other: Supportive Care","Treatment-related serious adverse events (tSAEs)|Change in clinical status at day 14","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-47561 MSC for COVID-19","February 12, 2021","October 2022","October 2022","April 14, 2020",,"October 6, 2021","Houston Methodist Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04345601"
13,"NCT03478215","Mesenchymal Stromal Cells in Living Donor Kidney Transplantation",,"Recruiting","No Results Available","Renal Transplantation|Mesenchymal Stem Cells","Biological: Mesenchymal Stromal Stem Cells (MSCs) Infusion|Other: Normal Saline (Placebo) Infusion","Number of participants without any infusional toxicity, occurring within 24 hours of infusion.|Number of participants without any acute rejection, graft loss, or death at 6 months post transplant.","The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","Pro00012858|U1111-1169-2289","December 2016","December 2023","December 2023","March 27, 2018",,"March 9, 2022","Houston Methodist Hospital System, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03478215"
14,"NCT01061099","Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta","STOD3","Completed","No Results Available","Osteogenesis Imperfecta Type II|Osteogenesis Imperfecta Type III","Biological: Mesenchymal Stromal Cells","To determine the safety or repeated infusions of donor-derived and MSCs in subjects with severe osteogenesis imperfecta > 5years after an allogeneic bone marrow transplant and no prior bone marrow transplant.|To determine if MSCs elicit an immune response after repeated infusions.|To determine the change in clinical course (growth, bone mineral content, fracture rate, development/activities) of subjects after experimental MSC intervention therapy as compared with each subject's own pre-MSC intervention therapy.","Nationwide Children's Hospital","All","up to 19 Years   (Child, Adult)","Phase 1","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-4-5947","February 2010","March 2013","February 2014","February 2, 2010",,"April 24, 2015","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01061099"
15,"NCT01659762","A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.","EPIC/MSC/IBD","Completed","No Results Available","Crohn's Disease","Biological: autologous mesenchymal stromal cell","Number of adverse events|Crohn's disease activity Index (CDAI)","Emory University|Atlanta Clinical and Translational Science Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00051454|EPIC001","July 2012","July 2015",,"August 8, 2012",,"October 17, 2016","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01659762"
16,"NCT03608631","iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation",,"Recruiting","No Results Available","KRAS NP_004976.2:p.G12D|Metastatic Pancreatic Adenocarcinoma|Pancreatic Ductal Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8","Drug: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA","Maximum Tolerated Dose Determined by Dose Limiting Toxicity|Minimal residual disease rate in high-risk patients|Overall survival (OS)|Progression-free survival (PFS)","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0126|NCI-2018-01441","January 27, 2021","March 31, 2023","March 31, 2023","August 1, 2018",,"April 26, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03608631"
17,"NCT00644410","Autologous Mesenchymal Stromal Cell Therapy in Heart Failure",,"Completed","No Results Available","Congestive Heart Failure","Biological: Mesenchymal stromal cell|Biological: Saline","Improvements in left ventricular function|Clinical improvements","Rigshospitalet, Denmark","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSC heart failure","September 2008","March 2015","March 2015","March 26, 2008",,"March 17, 2015","The Heart Centre, Rigshospitalet University Hospital Copenhagen,, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT00644410"
18,"NCT02260375","MSC Therapy in Liver Transplantation",,"Recruiting","No Results Available","Liver Transplant Rejection","Biological: Mesenchymal Stromal Cells","Number of adverse events|Liver tissue mRNA level of Transferrin receptor CD71 (TFRC) and Hepcidin antimicrobial peptide (HAMP) genes|Circulating naive and memory T cell conts (CD45RA/CD45RO)(flow cytometry analysis)|T-cell function in mixed lymphocyte reaction","Monia Lorini|Mario Negri Institute for Pharmacological Research|A.O. Ospedale Papa Giovanni XXIII","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC liver transplant tolerance|2014-001531-37","October 2014","October 2024","October 2025","October 9, 2014",,"April 6, 2018","U.S.C Nefrologia e Dialisi, Bergamo, Italy|USC Chirurgia Generale III, Bergamo, Italy|USC Ematologia, Bergamo, Italy|USC Gastroenterologia, Bergamo, Italy|Servizio di Immunoematologia e Medicina Trasfusionale, Bologna, Italy|Unità Chirurgia Generale e Trapianti, Bologna, Italy",,"https://ClinicalTrials.gov/show/NCT02260375"
19,"NCT04466098","Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)",,"Active, not recruiting","No Results Available","Acute Respiratory Distress Syndrome|ARDS (Moderate or Severe)|COVID-19 Pneumonia","Biological: Mesenchymal stromal cells|Other: Placebo","Incidence of grade 3-5 infusional toxicities and predefined hemodynamic or respiratory adverse events related to the infusion of MSC|Incidence of a reduction in one or more biomarkers of inflammation by day 7|Trend changes in PaO2:FiO2 ratio|Trend changes in Mean Airway Pressure|Trend changes in peak pressure|Trend changes in plateau pressure|Trend changes in Positive end-expiratory airway pressure (PEEP)|Incidence of mortality|Number of ICU-free days|Number of days alive and ventilator free composite score 3|Change in acute lung injury (ALI) score 2|Incidence of serious adverse events|Number of days alive off supplemental oxygen","Masonic Cancer Center, University of Minnesota","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2020LS075|MT2020-12","July 30, 2020","August 21, 2021","December 2022","July 10, 2020",,"February 28, 2022","University of Minnesota, Minneapolis, Minnesota, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04466098"
20,"NCT04255147","Cellular Therapy for Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia",,"Not yet recruiting","No Results Available","Bronchopulmonary Dysplasia","Biological: Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells","Occurrence and rate of dose limiting toxicity|Rate of Death|Occurrence of Other Severe Complications of Prematurity|FiO2 and Oxygen Index|Need for Ventilatory Support|Need for Postnatal Steroids|Incidence and Severity of BPD|Rate of Survival Without (moderate or severe) BPD|Changes in Pulmonary Hemodynamics|Biological Measure of Clinical Improvement|Biological Measure of Lung Improvement|Feasibility: Cell Administration|Feasibility: Recruitment Efficiency|Feasibility: Recruitment Timing|Feasibility: Participant Retainment|Bayley Scale of Infant and Toddler Development|Long-term Safety Follow-Up|Animated Information Video","Ottawa Hospital Research Institute|Canadian Institutes of Health Research (CIHR)|Ontario Institute of Regenerative Medicine (OIRM)|Stem Cell Network","All","7 Days to 21 Days   (Child)","Phase 1","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HULC-1","June 2022","June 2023","December 2035","February 5, 2020",,"April 21, 2022","The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04255147"
21,"NCT02805855","Autologous Culture Expanded Mesenchymal Stromal Cells for Knee Osteoarthritis",,"Active, not recruiting","No Results Available","Osteoarthritis, Knee","Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells","Number of subjects experiencing adverse events.","Jacob L. Sellon, M.D.|Mayo Clinic","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-008179","October 26, 2016","April 26, 2023","April 26, 2023","June 20, 2016",,"April 6, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02805855"
22,"NCT02580695","A Study to Assess Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells in Knee Osteoarthritis",,"Completed","No Results Available","Osteoarthritis","Biological: umbilical-cord mesenchymal stromal cells|Drug: Hyaluronic Acid","Proportion of patients who experience an adverse event|Physical function improvement measured by WOMAC OA index|Change in pain density measured by Visual analogue scale (VAS)|QoL improvement measured by SF-36|Changes in WORMS scale measured by knee MRI","Francisco Espinoza, MD|Universidad de los Andes, Chile","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C4COA01","December 2015","January 2017","April 2017","October 20, 2015",,"December 26, 2018","Clinica Universidad de los Andes, Santiago, Chile",,"https://ClinicalTrials.gov/show/NCT02580695"
23,"NCT02421484","Cellular Immunotherapy for Septic Shock: A Phase I Trial","CISS","Completed","No Results Available","Septic Shock","Biological: Allogeneic mesenchymal stromal cells","Number of adverse events as a measure of safety and tolerability","Ottawa Hospital Research Institute|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014809","May 2015","June 2016","October 30, 2018","April 20, 2015",,"October 31, 2018","The Ottawa Hospital, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02421484"
24,"NCT04328714","Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease",,"Recruiting","No Results Available","Acute Leukemia|Myelodysplastic Syndromes","Drug: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells","Number of successful preparations and deliveries of investigational product|Number of adverse events attributed to the investigational product|Maximal Tolerated Dose|Primary graft failure|Secondary graft failure|Platelet engraftment|Non-relapse mortality (NRM)|Change in Acute graft-versus-host disease (aGvHD) Incidence|Change in Chronic graft-versus-host disease (cGvHD) Incidence|Disease-free survival (DFS)|Primary cause of death|Relapse|Early discontinuation|Viral activation","Edwin Horwitz|Ossium Health, Inc.|Emory University","All","1 Year and older   (Child, Adult, Older Adult)","Phase 1","45","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00105305","December 2, 2021","August 2023","August 2023","March 31, 2020",,"July 19, 2022","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04328714"
25,"NCT03211793","Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis","MANUS","Recruiting","No Results Available","Systemic Sclerosis|Digital Ulcer","Drug: Mesenchymal stromal cells|Other: Placebo","Toxicity of the treatment|Serious adverse events|Change in perceived pain based on the Numerical Rating Scale|Change in perceived pain based on the digital ulcer visual analogue scale (part of the S-HAQ)|Change in perceived pain based on the pain VAS ( part of the S-HAQ)|Change in perceived pain based on the use of analgesics.|Quality of life - SF-36|Quality of life - Euroqol|Disability|Hand function|Number (and change in number) of digital ulcers|Healing of digital ulcers|Ulcer size|Time to healing of digital ulcers|Need to alter medication regime|Modified Rodnan Skin Score|Severity of Raynaud's symptoms|Changes in capillary morphology and architecture|Changes in laboratory parameters|Changes in circulating cell populations","UMC Utrecht|ZonMw: The Netherlands Organisation for Health Research and Development","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MANUS|2015-000168-32","October 6, 2021","November 1, 2023","November 1, 2023","July 7, 2017",,"March 22, 2022","Universitair Medisch Centrum Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03211793"
26,"NCT05035862","Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma",,"Recruiting","No Results Available","Asthma","Drug: Albuterol Sulfate|Drug: Interferon gamma-primed mesenchymal stromal cells (MSCs)|Drug: Prednisone","Change in number of adverse events and severe adverse events post-intervention|Number of grade ≥3 adverse reaction attributable to the γMSC product|Change in lung function test|In- vivo trafficking of MSCs after intravenous infusion|Upper airway inflammation of MSC treatment|Circulating inflammatory cells of MSC treatment|Biophysical characteristics of the cell products and correlation with clinical outcome","Emory University|The Marcus Foundation|Ossium Health, Inc.","All","18 Years to 30 Years   (Adult)","Phase 1","12","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STUDY00002655|2709","March 16, 2022","July 2023","July 2023","September 5, 2021",,"July 25, 2022","Children's Healthcare of Atlanta, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT05035862"
27,"NCT04361942","Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)","COVID_MSV","Completed","No Results Available","COVID-19 Pneumonia","Biological: Mesenchymal Stromal Cells|Other: Placebo","Proportion of patients who have achieved withdrawal of invasive mechanical ventilation|Rate of mortality|Proportion of patients who have achieved clinical response|Proportion of patients who have achieved radiological responses","Red de Terapia Celular|Citospin|University of Valladolid|Castilla-León Health Service|Hospital del Río Hortega|Instituto de Salud Carlos III","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TerCel_007|2020-001682-36","May 1, 2020","October 28, 2021","October 28, 2021","April 24, 2020",,"June 7, 2022","Hospital Universitario Rio Hortega, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04361942"
28,"NCT04615429","Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID-19 Pneumonia","Biological: Mesenchymal stromal cells|Other: Placebo","Change in the PaO2/FiO2* ratio from baseline to day 7 of treatment administration|All-cause mortality|Time to PaO2/FiO2 ratio greater than 200 mmHg|Clinical status on the World Health Organization ordinal scale|PaO2/FiO2 ratio|SOFA score|Oxygen therapy-free days|Duration of hospitalization|Duration of ICU admission|Incidence of non-invasive ventilation|Incidence of invasive mechanical ventilation|Duration of non-invasive ventilation|Duration of invasive mechanical ventilation|Mechanical ventilation-free days|Survival rate|Cumulative incidence SAEs, Grade 3 and 4 AEs, ADR and AEs of special interest.","Cristina Avendaño Solá|Puerta de Hierro University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","COVID-AT|2020-002193-27","September 15, 2020","January 2022","February 2022","November 4, 2020",,"November 10, 2021","Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04615429"
29,"NCT04356287","Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis","CARE-SSc","Not yet recruiting","No Results Available","Sclerosis, Systemic|Mesenchymal Stem Cells","Biological: UCMSC|Other: Placebo","Measure of safety one month after first infusion|Change in modified Rodnan skin score (mRss) between Month 0 and Month 12","Marie Hudson, MD|Medical University of South Carolina|McGill University Health Centre/Research Institute of the McGill University Health Centre|Université de Montréal|Assistance Publique - Hôpitaux de Paris|Centre hospitalier de l'Université de Montréal (CHUM)|University Paris 7 - Denis Diderot|Sir Mortimer B. Davis - Jewish General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP-05-2020-2251","May 2022","April 2024","April 2025","April 22, 2020",,"April 1, 2022",,,"https://ClinicalTrials.gov/show/NCT04356287"
30,"NCT03901235","MSC Intratissular Injection in Crohn Disease Patients","MSC","Recruiting","No Results Available","Efficacy and Safety","Biological: Mesenchymal Stromal Cells","Proportion of patients with deep ulcer healing|Proportion of patients with stricture healing|Proportion of patients with complex perianal fistula healing|Safety assessed by the incidence of treatment-emergent adverse events during the study period|Evolution of clinical disease activity index|Evolution of Short health scale (quality of life)|Evolution of the Lemann Index (measuring cumulated intestinal damage in Crohn's disease)|Evolution of the "" Group of Therapeutic Study of Inflammatory Disorders of the Digestive Tube"" obstructive score for Crohn Disease strictures","University of Liege|Centre Hospitalier Universitaire de Liege","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TJT1707P1","January 15, 2018","December 31, 2022","December 31, 2023","April 3, 2019",,"November 26, 2021","CHU de Liège, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT03901235"
31,"NCT00957931","Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs",,"Completed","Has Results","Sickle Cell Disease|Thalassemia|Diamond-Blackfan Anemia","Procedure: Bone marrow transplantation|Biological: Mesenchymal Stromal Cells","Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT)|Overall Survival 6 Months Following HCT|Overall Survival 1 Year Following HCT|Count of Participants With Disease-free Survival 6 Months Following HCT|Count of Participants With Disease-free Survival 1 Year Following HCT","Stanford University|University of Minnesota|University of Alabama at Birmingham","All","1 Year to 25 Years   (Child, Adult)","Phase 2","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC01","March 2009","August 2013","August 2013","August 13, 2009","August 6, 2018","August 6, 2018","Children's Hospital of Alabama, Birmingham, Alabama, United States|University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00957931"
32,"NCT01306513","Safety and Feasibility Study of Administration of Mesenchymal Stemcells for Treatment of Emphysema",,"Completed","No Results Available","Emphysema","Biological: autologous bone marrow derived mesenchymal stromal cells","Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Leiden University Medical Center","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL28562.000.09","October 2010","June 2012","November 2012","March 2, 2011",,"November 19, 2012","Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT01306513"
33,"NCT02384018","Mesenchymal Stem Cell and Islet Co-transplantation",,"Completed","No Results Available","Chronic Pancreatitis|Diabetes","Biological: autologous mesenchymal stromal cell","C-peptide level after mixed meal tolerance test|Liver function, kidney function|The absence of severe hypoglycemic episodes","Medical University of South Carolina|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 1","3","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCT-BMMSC15-001|5R21DK099696","December 2014","June 1, 2016","November 21, 2017","March 10, 2015",,"April 4, 2022","GI Surgery, Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02384018"
34,"NCT04236479","Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)",,"Recruiting","No Results Available","Congenital Heart Disease (CHD)","Biological: BM-MSC","Number of subjects who experience serious adverse events, adverse events, and/or early treatment discontinuations.|Actual magnitude of differences in neuroimaging and neurodevelopmental variables will be measured after MSC delivery.","Catherine Bollard|Children's National Research Institute","All","up to 6 Months   (Child)","Phase 1","36","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00011914","July 29, 2020","September 2024","April 2025","January 22, 2020",,"May 13, 2022","Children's National Health System, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT04236479"
35,"NCT04400032","Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome","CIRCA-19","Completed","No Results Available","Acute Respiratory Distress Syndrome|Covid19","Biological: Mesenchymal Stromal Cells","Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Number of Participants alive by Day 28|Number of Participants with ventilator-free Days by Day 28","Ottawa Hospital Research Institute|Stem Cell Network|Ontario Research Fund","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20200243-01H","May 15, 2020","April 22, 2021","April 22, 2021","May 22, 2020",,"April 26, 2021","The Ottawa Hospital, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04400032"
36,"NCT04626583","Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells",,"Recruiting","No Results Available","Mesenchymal Stromal Cells|Cornea|Safety|Corneal Defect","Biological: Allogeneic MSC","Primary Safety Outcome: Incidence of treatment emergent adverse events (TEAE) assessed at 28 days.|Primary Efficacy Outcome: Proportion of participants with improvement in epithelial defect or barrier integrity relative to baseline (based on fluorescein staining)|Secondary Efficacy Outcomes: Visual Acuity|Secondary Efficacy Outcomes: Time to Completion of Corneal Epithelialization|Secondary Efficacy Outcomes: Durability of the Corneal Epithelialization and Healing|Secondary Efficacy Outcomes: Corneal stromal haze|Secondary Efficacy Outcomes: Corneal epithelial thickness","University of Illinois at Chicago|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-0334|W81XWH-18-1-0661","March 5, 2021","December 30, 2023","December 30, 2023","November 12, 2020",,"April 21, 2022","University of Illinois, Department of Ophthalmology and Visual Sciences, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04626583"
37,"NCT05061030","Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents",,"Recruiting","No Results Available","Type1diabetes","Biological: the ATMP Protrans","Safety at one year evaluated as adverse events|Safety at five years evaluated as adverse events|Efficacy measured as change in C-peptide Area under the curve to a mixed mealtolerance test.|Insulin independency|Low insulin needs|Insulin needs|HbA1c|Time in target|Time in range|C-peptide|Change in peak C-peptide","Uppsala University Hospital","All","7 Years to 21 Years   (Child, Adult)","Phase 1|Phase 2","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WJMSC-P01","January 14, 2022","September 2028","December 2028","September 29, 2021",,"May 23, 2022","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT05061030"
38,"NCT02359929","BMT Autologous MSCs for GvHD",,"Completed","No Results Available","Graft Versus Host Disease|Acute Graft Versus Host Disease|Chronic Graft Versus Host Disease","Biological: Autologous mesenchymal stromal cells (MSCs)","Safety and Tolerability of EPIC MSC2014-002 based on dose limiting toxicities (DLTs)|Overall Response Rate for acute GVHD subjects|Overall Response Rate for chronic GVHD subjects|Transplant-related mortality|Incidence of Relapse|Disease-free survival|Overall-survival","Emory University|CURE Foundation","All","12 Years and older   (Child, Adult, Older Adult)","Phase 1","11","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00076372","January 2015","June 15, 2020","January 11, 2021","February 10, 2015",,"March 4, 2021","Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02359929"
39,"NCT02495766","Autologous Mesenchymal Stromal Cells for Multiple Sclerosis","EMMES","Completed","No Results Available","Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis","Drug: XCEL-MC-ALPHA|Drug: Placebo","Adverse events|Cumulative number of MRI Gd-enhancing lesions|Multiple Sclerosis Outbreaks|Expanded Disability Status Scale (EDDS) score|Cumulative number of lesions visualized on T2 sequence","Banc de Sang i Teixits|Vall d'Hebron Research Institute (VHIR)","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XCEL-MS-02","May 11, 2015","November 27, 2017","November 15, 2018","July 13, 2015",,"January 21, 2020","Hospital Vall Hebron, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02495766"
40,"NCT04034316","Reduce Immunosuppression With Atmp in NS ChildrEn","RACE","Enrolling by invitation","No Results Available","Nephrotic Syndrome in Children|Steroid-Dependent Nephrotic Syndrome|Idiopathic Nephrotic Syndrome","Other: Cord-blood mesenchymal stromal cells","The percentage of patients without nephrotic syndrome recurrence after complete withdrawal of immunosuppressive treatment for at least 6 months|The percentage of adverse events|The time to recurrence of nephrotic syndrome|The percentage of participants achieving a reduction in the immunosuppressive therapy|The dose of immunosuppressive therapy to prevent further NS relapses|Reported Quality of Life","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Cell Factory Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico|Laboratorio Sperimentale di Immunologia e Trapianti, Oncoematologia Pediatrica, Fondazione IRCCS Policlinico S. Matteo, Pavia","All","3 Years to 18 Years   (Child, Adult)","Phase 2","11","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIFA-2016-02364896|2018-001162-42","November 2, 2018","June 30, 2022","December 2022","July 26, 2019",,"August 26, 2021","Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan, Milan, MI, Italy",,"https://ClinicalTrials.gov/show/NCT04034316"
41,"NCT04675359","Adipose-derived MSCs After Enzymatic Digestion vs. Mechanically Fragmented Fat Transfer in Knee Osteoarthritis Treatment",,"Not yet recruiting","No Results Available","Knee Osteoarthritis|Chondropathy","Procedure: Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint","Changes in patients reported outcome measures - Knee Injury and Osteoarthritis Outcome Score (KOOS)|Changes in flexibility of the knee joint|Changes in X-ray imaging of the knee joint in a standing position (AP view)|Changes in MRI with T-2 Mapping of the knee cartilage","Medical University of Warsaw","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MSC","July 1, 2021","June 30, 2023","December 1, 2023","December 19, 2020",,"January 8, 2021",,,"https://ClinicalTrials.gov/show/NCT04675359"
42,"NCT01860417","Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)","Disc_allo","Completed","No Results Available","Degenerative Disc Disease|Intervertebral Disc Disease|Low Back Pain","Biological: Allogenic Mesenchymal Stromal Cells|Drug: Mepivacaine","Safety and tolerability|Pain and disability evolution|Evolution of affected disc(s) by quantitative Magnetic Resonance Imaging (RMI)|Llife quality evolution (Short Form (SF)-12 questionnaire)","Red de Terapia Celular|Citospin|University of Valladolid","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","25","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","TerCel005|2012-004444-30|Disc_allo_MSV","April 2013","April 2017","April 2017","May 22, 2013",,"April 26, 2017","Hospital Clinico Universitario, Valladolid, Spain|Instituto de Biologia y Genetica Molecular, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT01860417"
43,"NCT04089579","hCT-MSC in Children With Autism Spectrum Disorder","IMPACT","Recruiting","No Results Available","Autism|Autism Spectrum Disorder","Biological: Cord Tissue Mesenchymal Stromal Cells|Other: Placebo Infusion","Change on the Socialization and Communication Subscale Standard Scores on the Vineland Behavior Scales|Change in VABS-3 Socialization Standard Score|Change in VABS-3 Communication Standard Score|Change in CGI-Severity score|CGI-Intervention score|Change in the Pediatric Quality of Life Scale","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","4 Years to 11 Years   (Child)","Phase 2","164","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00102894","October 12, 2020","February 1, 2023","August 1, 2023","September 13, 2019",,"February 18, 2022","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04089579"
44,"NCT03522545","Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression",,"Recruiting","No Results Available","Treatment-resistant Bipolar Depression","Biological: Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)|Biological: Placebo","Change in depression as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS)|Change in Functional impairment as assessed by the Functioning Assessment Short Test (FAST)|Change in Overall functioning in living as assessed by the Global Assessment of Functioning (GAF)|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity of mania subscale|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity of depression subscale|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity overall subscale|Change in neurocognition as assessed by the California Verbal Learning Test|Change in problem-solving ability as assessed by the Wisconsin Card Sorting Test (WCST)|Number of participants with inflammatory markers as assessed by multiplex biomarker analysis|Change in brain-derived neurotrophic factor (BDNF) level as assessed by enzyme-linked immunosorbent assay (ELISA)|Change in C-reactive protein (CRP) level as assessed by enzyme-linked immunosorbent assay (ELISA)|Number of participants with a change in brain activity between baseline and week 26 as assessed by Magnetic Resonance Imaging (MRI)|Number of participants who withdrawal due to Adverse Events (AEs)|Number of participants with suicidal ideation based on clinical assessment|Number of participants with treatment emergent mania or hypomania as assessed by the Young Mania Rating Scale (YMRS) and clinical assessment","The University of Texas Health Science Center, Houston","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-16-0657","June 1, 2021","July 1, 2024","July 1, 2024","May 11, 2018",,"September 7, 2022","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03522545"
45,"NCT01586312","Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells","MSV_allo","Completed","Has Results","Osteoarthritis, Knee|Arthritis of Knee|Knee Osteoarthritis","Other: Allogenic mesenchymal stromal cells injection|Drug: Hyaluronic Acid","Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Pain and Disability Evolution (WOMAC, Visual Analogue Scale, Lequesne Index and SF-12 Scores)|Evolution of Cartilage Degeneration by T2 Relaxation Measurements in MRI (Cartigram)","Red de Terapia Celular|University of Valladolid|Sanidad de Castilla y León|Centro Medico Teknon","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","TerCel004|2011-005321-51|EC11-309|MSV_allo","April 2012","December 2013","June 2014","April 26, 2012","November 6, 2014","October 16, 2015","Centro Medico Teknon, Barcelona, Spain|Hospital Clinico Universitario, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT01586312"
46,"NCT03608579","Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA",,"Recruiting","No Results Available","Osteoarthritis, Hip","Drug: Autologous Adipose Derived Mesenchymal Stromal Cells","Nature, incidence and severity of adverse events (AEs)|Change in Visual Analog Scale (VAS) for pain in the target hip following completion of treatment cycles|Change in Tegner activity scale in the target hip following completion of treatment cycles|Change in modified Harris Hip Score (mHHS) in the target hip following completion of treatment cycles|Change in Hip disability and osteoarthritis Outcome Score (HOS) in the target hip following completion of treatment cycles|Change in radiographic joint morphology|Change in cartilage thickness|Change in cartilage volume|Change in cartilage morphology|Change in subchondral bone morphology|Change periarticular soft-tissues|Change in synovial fluid biomarkers within the target hip","Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-000015","November 5, 2018","December 2022","December 2022","August 1, 2018",,"December 17, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03608579"
47,"NCT04714801","Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation",,"Recruiting","No Results Available","Lung Transplant Rejection","Drug: adipose derived mesenchymal stromal cells|Drug: Saline","Pulmonary graft dysfunction (PDG)|Kidney glomerular Filtration Rate|Inflammatory markers","Rigshospitalet, Denmark","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ASC Lungtransplantation","October 1, 2020","November 30, 2023","November 30, 2024","January 19, 2021",,"July 16, 2021","2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04714801"
48,"NCT01909154","Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic Paraplegia","CME-LEM1","Completed","Has Results","Spinal Cord Injury","Biological: Mesenchymal stromal cell therapy","Safety-Number of Adverse Events|Efficacy-Sensitivity Recovery Using ASIA Scale|Efficacy-Changes in the Level of Chronic Pain Based on the IANR-SCIFRS Scale (Pain Section)|Efficacy- Changes in the Neurophysiological Parameters Measured as the Number of Patients With SSEPs (Somatosensory Evoked Potentials)|Efficacy-Urodynamic Studies in Terms of máximum Cystometric Capacity|Efficacy-modification of Magnetic Resonance Imaging (MRI)","Puerta de Hierro University Hospital","All","18 Years to 60 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CME-LEM1|2010-023285-46","March 2013","April 2014","March 2015","July 26, 2013","March 29, 2019","March 29, 2019","Hospital Puerta de Hierro, Majadahonda, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01909154"
49,"NCT04971161","Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)",,"Recruiting","No Results Available","Skin Ulcer Venous Stasis Chronic","Biological: allo-APZ2-CVU|Drug: Placebo","Complete wound closure at Week 18 already persisting for at least two weeks|Assessment of adverse event (AE) occurrence|Wound size change in percent at each post-baseline follow-up visit|Time to complete wound closure|Complete wound closures at each post-baseline follow-up visit|Duration of wound closure|Recurrence of the wound|Quality of wound healing (wound exudate) at each post-baseline follow-up visit|Quality of wound healing (granulation tissue together with epithelialization) at each post-baseline follow-up visit|Quality of wound healing (scar formation) at each post-baseline follow-up visit|Assessment of Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14|Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit|Physical examination and vital signs at V14","RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Ticeba GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","allo-APZ2-CVU-IIb","August 18, 2021","August 2023","August 2023","July 21, 2021",,"September 21, 2022","Universitätsklinikum Augsburg, Klinik für Dermatologie und Allergologie, Campus Süd, Augsburg, Germany|Fachklinik Bad Bentheim, Dermatologische Ambulanz, Bad Bentheim, Germany|Franziskus-Krankenhaus Berlin, Klinik für Innere Medizin, Angiologie und Diabetologie, Berlin, Germany|Helios Klinikum Berlin-Buch, Klinik für Plastische und Ästhetische Chirurgie, Berlin, Germany|Helios Klinikum Emil von Behring, Klinik für Plastische und Ästhetische Chirurgie, Berlin, Germany|Hautarztpraxis Dr. Niesmann & Dr. Othlinghaus, Hautzentrum im Jahrhunderthaus, Bochum, Germany|Katholisches Klinikum Bochum gGmbH, Venenzentrum der Kliniken für Dermatologie und Gefäßchirurgie der Ruhr-Universität Bochum, Bochum, Germany|Hautärzte Braunschweig am Altstadtmarkt, Hautärztliche Gemeinschaftspraxis, Braunschweig, Germany|Klinikum Bremerhaven Reinkenheide gGmbH, Klinik für Dermatologie, Allergologie und Phlebologie, Wundzentrum, Bremerhaven, Germany|Klinische Forschung Dresden GmbH, Dresden, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Medizinische Klinik und Poliklinik III Angiologie und Gefäßzentrum, Dresden, Germany|Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Klinik für Dermatologie, Düsseldorf, Germany|Universitätsklinikum Erlangen, Hautklinik - Wundzentrum Dermatologie, Erlangen, Germany|Universitätsklinikum Essen, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Essen, Germany|Universitätsklinikum Freiburg, Klinik für Dermatologie und Venerologie, Freiburg, Germany|Marienhospital Gelsenkirchen GmbH, Klinik für Chirurgie (Allgemein-, Viszeral- und Endokrine Chirurgie, Thorax-, Gefäß- und Endovaskuläre Chirurgie und Kinderchirurgie), Gelsenkirchen, Germany|SRH Wald-Klinikum Gera GmbH, Zentrum für Klinische Studien, Gera, Germany|Praxis Dr. med. Abdou Zarzour, Halle, Germany|Universitätsklinikum Hamburg- Eppendorf, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP), Hamburg, Germany|MVZ Prof. Dr. Ockenfels, Haut und Allergie-Praxisklinik GmbH, Hanau, Germany|SRH Klinikum Karlsbad- Langensteinbach GmbH, Interdisziplinäres Gefäßzentrum Innere Medizin, Karlsbad, Germany|Medizinisches Versorgungszentrum DermaKiel GmbH, Kiel, Germany|Helios Klinikum Krefeld, Klinik für Dermatologie und Venerologie, Krefeld, Germany|Hautarztpraxis Langenau, Studienzentrum, Langenau, Germany|Universitätsklinikum Leipzig AöR, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Leipzig, Germany|Studienambulanz Dr. Schubert Leipzig, Leipzig, Germany|Diabetologikum Ludwigshafen, die Praxis am Ludwigsplatz, Ludwigshafen, Germany|Beldio Research GmbH, Memmingen, Germany|Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Dermatologie und Allergologie, München, Germany|Dermazentrum München, Standort Neuhausen, Studienzentrum, München, Germany|Universitätsklinikum Münster, Klinik für Hautkrankheiten, Allgemeine Dermatologie und Venerologie, Münster, Germany|Klinikum Nürnberg Nord, Klinik für Dermatologie, Nürnberg, Germany|Hautarztpraxis Prof. Dr. med. Khusru Asadullah, Potsdam, Germany|Caritas-Krankenhaus St. Josef, Klinik für Plastische und Ästhetische, Hand- und Wiederherstellungschirurgie, Regensburg, Germany|Universitätsmedizin Rostock, Klinik und Poliklinik für Dermatologie und Venerologie, Rostock, Germany|Helios Kliniken Schwerin, Plastische, Rekonstruktive und Ästhetische Chirurgie, Schwerin, Germany|Hautärztliche Gemeinschaftspraxis Dr. Leitz und Kollegen, Stuttgart, Germany|Universitätsklinikum Tübingen, Universitäts-Hautklinik Tübingen, Tübingen, Germany|Helios Universitätsklinikum Wuppertal, Zentrums für Dermatologie, Allergologie und Dermatochirurgie, Wuppertal, Germany|Universitätsklinikum Würzburg, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT04971161"
50,"NCT01175655","A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation","MSC in OB","Completed","No Results Available","Bronchiolitis Obliterans|Lung Transplantation","Other: MSC","To establish the safety of infusions of MSC from related or unrelated HLA identical or HLA mismatched donors in the management of bronchiolitis obliterans syndrome after lung transplantation.|To document changes in lung function and 6 minute walk distance (6MWD) following infusion of MSC|To document survival post MSC infusion","The Prince Charles Hospital|Cell and Tissue Therapies Western Australia","All","Child, Adult, Older Adult","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC 28105","February 2010","July 2015","July 2016","August 5, 2010",,"April 26, 2022","TPCH, Brisbane, Queensland, Australia|RPH, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT01175655"
51,"NCT01872624","Safety Study of Bone-marrow Derived Mesenchymal Stromal Cells Associated With Endobronchial Valves in Emphysema",,"Completed","No Results Available","Pulmonary Emphysema","Procedure: Bronchoscopy","Absence of lung deficits during the procedure and/or in the 4 months follow-up|Quality of Life|Pulmonary function|Inflammation","Hospital de Clinicas de Porto Alegre|Ministry of Health, Brazil|National Research Council, Brazil|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Rio de Janeiro State Research Supporting Foundation (FAPERJ)|Universidade Federal do Rio de Janeiro|Pontifícia Universidade Católica do Paraná","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-0150","May 2013","December 2014","March 2015","June 7, 2013",,"March 25, 2015","Pontificia Universidade Catolica do Parana, Curitiba, PR, Brazil|Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil",,"https://ClinicalTrials.gov/show/NCT01872624"
52,"NCT03917797","Mesenchymal Stromal Cells (MSC´s) in Renal Lupus","MSC-ROLE","Recruiting","No Results Available","Lupus Erythematosus, Systemic|Lupus Glomerulonephritis","Biological: MSC treatment|Drug: Standard of Care|Drug: Placebo","Achievement of Global Renal Response (GR) at Study Endpoint|Achievement of Complete Renal Response (CR) at Study Endpoint|Achievement of Partial Renal Response (PR) at Study Endpoint|Treatment Failure|Response of SLE Responder Index (SRI).|Selena Sledai|BILAG score|Disease Flares|Biomarker Response","Universidad de los Andes, Chile","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Phase II Lupus MSC","April 2, 2019","December 2022","December 2022","April 17, 2019",,"November 16, 2020","Clínica Universidad de los Andes, Santiago de Chile, Región Metropolitana, Chile|Hospital Barros Luco Trudeau, Santiago de Chile, Región Metropolitana, Chile",,"https://ClinicalTrials.gov/show/NCT03917797"
53,"NCT02230514","Mesenchymal Stromal Cells for the Treatment of Non-union Fractures of Long Bones",,"Completed","No Results Available","Atrophic Nonunion of Fracture","Drug: XCEL-MT-OSTEO-ALPHA|Other: autologous iliac crest|Procedure: Surgery","Efficacy assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures by imaging procedures|Safety assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures|Efficacy assessment by quality of life test","Banc de Sang i Teixits|Hospital ASEPEYO Sant Cugat","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","XCEL-PSART-01|2013-005025-23","November 20, 2014","March 5, 2019","December 20, 2019","September 3, 2014",,"April 12, 2021","Hospital ASEPEYO Sant Cugat, Sant Cugat, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02230514"
54,"NCT03209700","Re-treatment From a Phase I Study of MSC-AFP in Patients With Perianal Fistulas","MSC-AFP","Completed","No Results Available","Perianal Fistula|Cryptoglandular Perianal Fistula|Crohn's Perianal Fistula","Drug: MSC-AFP","Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.","William A. Faubion, M.D.|Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-004503","July 20, 2017","December 10, 2019","December 10, 2019","July 6, 2017",,"January 3, 2020","Mayo Clinic in Minnesota, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03209700"
55,"NCT02807389","Stem Cell Fistula Plug in Post Surgical Leak Fistulas",,"Completed","No Results Available","Surgical Leak Fistula","Drug: MSC Fistula Plug","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Incidence of Fistula Closure","Mayo Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-004326","March 14, 2017","April 2, 2019","April 2, 2019","June 21, 2016",,"April 23, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02807389"
56,"NCT03449069","Pediatric MSC-AFP Sub-study for Crohn's Fistula",,"Recruiting","No Results Available","Fistula in Ano|Crohn Disease","Drug: MSC-AFP","Number of participants with treatment-related adverse events (safety and toxicity)|Number of participants with response to the treatment regarding cessation of drainage from the treated fistula.|Number of participants with radiographic response to the treatment regarding the treated fistula.","Mayo Clinic","All","12 Years to 17 Years   (Child)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-010539","July 23, 2018","February 28, 2023","February 28, 2023","February 28, 2018",,"March 31, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03449069"
57,"NCT02589119","Stem Cell Fistula Plug in Cryptoglandular Perianal Fistulas (MSC-AFP)",,"Completed","No Results Available","Perianal Fistula|Cryptoglandular Perianal Fistula","Drug: MSC-AFP","Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.","Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-003200","January 2016","September 2019","September 2019","October 28, 2015",,"December 6, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02589119"
58,"NCT03220243","Stem Cell Coated Fistula Plug in Patients With Crohn's RVF",,"Completed","No Results Available","Fistula Vagina|Crohn Disease","Drug: MSC-AFP","Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.","Mayo Clinic","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-002892","October 19, 2017","September 20, 2020","September 20, 2020","July 18, 2017",,"October 30, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03220243"
59,"NCT01449032","MesenchYmal STROMAL CELL Therapy in Patients With Chronic Myocardial Ischemia (MyStromalCell Trial)","MyStromalCell","Completed","No Results Available","Chronic Ischemic Heart Disease","Biological: MSC|Biological: Saline","Exercise test|Clinical evaluation","Rigshospitalet, Denmark","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MyStromalCell","April 2010","January 2014","January 2014","October 7, 2011",,"June 10, 2014","Rigshospitalet University Hospital Copenhagen, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT01449032"
60,"NCT01038596","Mesenchymal Stromal Cells and Osteoarthritis",,"Completed","No Results Available","Osteoarthritis",,"Global Gene expression profile of bone marrow-derived mesenchymal stromal cells from osteoarthritic versus healthy donors|Flow cytometric analysis of cell surface antigens, Alkaline phosphatase activity, DNA content as measure for cellular proliferation","Technische Universität Dresden|German Federal Ministry of Education and Research","All","50 Years to 90 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","HipMSC-Osteoarthritis","January 2009","June 2016","December 2016","December 24, 2009",,"April 14, 2017","University Hospital Dresden, Orthopaedic Department, Dresden, Germany",,"https://ClinicalTrials.gov/show/NCT01038596"
61,"NCT05465096","Treatment of Osteoarthritis of the Hip Joint With Intra-articular Injection of Microfractured Autologous Adipose Tissue Containing Mesenchymal Stromal Cells.","Lipo-Hip","Not yet recruiting","No Results Available","Hip Osteoarthritis|Hip Disease","Procedure: Micro-fragmented adipose tissue injection","Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)|Visual Analogue Scale (VAS)|Harris Hip Scale (HHS)","Istituto Ortopedico Rizzoli","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Lipo-Hip","September 2022","March 2023","September 2024","July 19, 2022",,"July 25, 2022","Istituto Ortopedico Rizzoli, Bologna, Italy",,"https://ClinicalTrials.gov/show/NCT05465096"
62,"NCT04489732","MSC in Patients With Xerostomia Post XRT in Head and Neck Cancer",,"Recruiting","No Results Available","Xerostomia Following Radiotherapy","Biological: Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells","Percentage of subjects experiencing dose limiting toxicity (DLT)|Change in Saliva production rate|Saliva composition analysis: Change in salivary pH|Saliva composition analysis: Change in total protein concentration in saliva|Saliva composition analysis: Change in amylase concentration in saliva|Saliva composition analysis: Change in mucin concentration in saliva|Change in The University of Michigan Xerostomia Related Quality of Life (XeQOL) score|Change in The MD Anderson Dysphagia Index (MDADI) score|Change in Visual Analogue Scale (VAS) xerostomia score|Change in salivary gland size|Change in salivary gland stiffness measured by shear wave velocity|Participant Drop out Rate","University of Wisconsin, Madison|University of Wisconsin Carbone Cancer Center (UWCCC)|National Institute of Dental and Craniofacial Research (NIDCR)","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","12","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-1290|A533300|SMPH/HUMAN ONCOLOGY/HUMAN ONCO|UW20025|NCI-2021-00070|1UG3DE030431-01|Protocol Version 10/7/2021|Head & Neck SPORE","February 18, 2022","June 2023","May 2024","July 28, 2020",,"March 22, 2022","University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04489732"
63,"NCT05456243","Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients",,"Recruiting","No Results Available","Kidney Transplant","Biological: Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)|Biological: High dose adipose tissue derived mesenchymal stromal cells (A-MSC)","Worsening kidney allograft rejection|Adverse Events","Mayo Clinic","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","21-012522","October 2022","August 2025","August 2025","July 13, 2022",,"September 9, 2022","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05456243"
64,"NCT03828123","Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis","AMSC-ALS-001","Completed","No Results Available","Motor Neuron Disease, Amyotrophic Lateral Sclerosis","Biological: Suspension of human autologous MSC 3P in 1.5 ml","Safety: Complications related to the medicinal product application - new neurological deficit and occurrence of other adverse events|Efficacy: Inhibition of the disease progression - ALS functional rating scale|Efficacy: Inhibition of the disease progression - Norris scale|Efficacy: Inhibition of the disease progression - Forced vital capacity (FVC)","Bioinova, s.r.o.|Department of Neurology, University Hospital Motol, Prague, Czech Republic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","26","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMSC-ALS-001","January 2012","August 18, 2017","August 18, 2017","February 4, 2019",,"February 12, 2019",,,"https://ClinicalTrials.gov/show/NCT03828123"
65,"NCT05204329","Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease","MSC Secretome","Not yet recruiting","No Results Available","Mesenchymal Stromal Cells|Cornea|Corneal Defect|Corneal Epithelium Defect","Biological: MSC Secretome Eye Drops","Epithelial Status Assessment|Visual Acuity|Corneal Epithelial thickness|Corneal Scarring / Haze|Tolerability of MSC secretome drops|Durability of Corneal Epithelial Status Improvement|Time to Improvement of Corneal Epithelial Barrier","University of Illinois at Chicago|National Institutes of Health (NIH)|National Eye Institute (NEI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","18","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021-0754|1UG3EY031809-01","December 1, 2022","January 1, 2025","January 1, 2025","January 24, 2022",,"January 24, 2022",,,"https://ClinicalTrials.gov/show/NCT05204329"
66,"NCT03973827","Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed With Type I Diabetes",,"Active, not recruiting","No Results Available","Type1diabetes","Drug: ProTrans","The primary safety endpoint in this study is; safety parameters include adverse events, hypoglycemia and allergic reactions|Delta-change of C-peptide AreaUnder the Curve (AUC) (0-120 min) for Mixed Meal Tolerance Test (MMTT) at day 372 following WJMSC infusion when compared to test performed before start of treatment.|Number of patients insulin independent (ADA criteria) at day 372.|Number of patients with daily insulin needs <0.25U/kg at day 372.|HbA1c at day 372|Glucose variability (mean amplitude of glycaemic excursions and glycaemic lability index) duration derived from the continuous glucose monitoring system® at day 372|Delta change of levels of fasting C-peptide at day 372 when compared to test before start of treatment|Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372.","NextCell Pharma Ab","Male","18 Years to 41 Years   (Adult)","Phase 1|Phase 2","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ProTrans-Repeat|2018-004158-11","May 17, 2019","December 10, 2020","October 30, 2024","June 4, 2019",,"January 11, 2022","Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge, Huddinge, Sweden",,"https://ClinicalTrials.gov/show/NCT03973827"
67,"NCT02709343","Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction","ASSIST-CLAD","Active, not recruiting","No Results Available","Chronic Lung Allograft Dysfunction (CLAD)","Drug: Bone-marrow derived MSCs|Drug: Placebo","Progression-free survival|Time to fall in FEV1 > 10%|Freedom from Bronchiolitis Obliterans Syndrome (BOS) grade 3|All cause mortality|CLAD-specific mortality|Freedom from acute rejection|Freedom from the development of new donor specific anti-HLA antibodies|Freedom from CLAD progression|Rate of FEV1 decline|Rate of FVC decline|Change in 6-minute walk distance (6MWD)|Change in St George's Respiratory Questionnaire (SGRQ) Score|Inpatient bed-days","The University of Queensland|Isopogen|Cell and Tissue Therapies","All","18 Years and older   (Adult, Older Adult)","Phase 2","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ASSIST-CLAD","April 21, 2017","July 2023","July 2023","March 16, 2016",,"August 24, 2022","St Vincents Hospital, Sydney, New South Wales, Australia|The Prince Charles Hospital, Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT02709343"
68,"NCT05490173","The Pilot Experimental Study of the Neuroprotective Effects of Exosomes in Extremely Low Birth Weight Infants",,"Not yet recruiting","No Results Available","Premature Birth|Extreme Prematurity|Preterm Intraventricular Hemorrhage|Hypoxia-Ischemia, Cerebral|Neurodevelopmental Disorders","Other: Exosomes derived from mesenchymal stromal cells (MSCs)","Occurrence and rate of dose limiting toxicity|Rate of death|Occurrence of Other Severe Complications of Prematurity|Need for Ventilatory Support|Changes in Hemodynamics|Feasibility: Administration|Feasibility: Recruitment Efficiency|Feasibility: Recruitment Timing|Feasibility: Participant Retainment|Griffiths-II and Bayley Scales of Infant Development (2nd edition)|Long-term Safety Follow-Up","Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare","All","1 Day to 3 Days   (Child)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","ncagp4382277","September 5, 2022","May 22, 2026","December 28, 2026","August 5, 2022",,"August 5, 2022","Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT05490173"
69,"NCT02585622","NEPHSTROM for Diabetic Kidney Disease","NEPHSTROM","Recruiting","No Results Available","Diabetic Kidney Disease","Biological: Mesenchymal Stromal Cells|Other: Placebo","Number and severity of all pre-specified infusion-associated events and the overall number and frequency of adverse events.|Glomerular filtration rate (GFR)|Urinary Albumin/Creatinine Ratio (ACR)|Urinary albumin excretion (UAE).|Fasting blood glucose (target <126mg/dL)|HbA1c (target <75mmol/mol or <9%)|Total cholesterol (target <200 mg/dl)|LDL cholesterol (target <100 mg/dl)|Triglycerides (target <170 mg/dl)|Arterial blood pressure (the target value <130/80 mmHg)|Quality of life|Anti-HLA antibody development|Inflammation and fibrosis related soluble mediators|Serum/plasma concentrations (pg/ml) of biomarkers of inflammation.|Serum/plasma concentrations (ng/ml) of biomarkers of CKD progression.|Urine concentrations (pg/ml adjusted to urine creatinine concentration) of biomarkers of inflammation.|Proportion/total number of circulating T cells, B cells, NK cells, monocytes, dendritic cells|Cost-effectiveness of cell therapy","Mario Negri Institute for Pharmacological Research|Leiden University Medical Center|ASST Papa Giovanni XXIII, Bergamo, Italy|IRCCS - Istituto di Ricerche Farmacologiche Mario Negri - Bergamo, Italy|Belfast Health and Social Care Trust|National University of Ireland, Galway, Ireland|University Hospital Birmingham, NHS Foundation Trust, Hospital, Birmingham, UK|NHS Blood and Transplant","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","NEPHSTROM|2016-000661-23","December 11, 2017","December 2021","July 2022","October 23, 2015",,"July 14, 2021","National University of ireland - Galway University Hospital -Regenerative Medicine Institute, Galway, Ireland|ASST - Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/ Mario Negri Institute for Pharmacological Research - Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Bergamo, BG, Italy|Belfast Health and Social Care Trust - Belfast City Hospital, Belfast, United Kingdom|University Hospital Birmingham NHS Foundation Trust - Queen Elizabeth Medical Centre, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02585622"
70,"NCT05464381","Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)",,"Not yet recruiting","No Results Available","Epidermolysis Bullosa","Drug: allo-APZ2-OTS|Drug: Placebo","Proportion of subjects with complete target wound closure","RHEACELL GmbH & Co. KG","All","Child, Adult, Older Adult","Phase 3","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","allo-APZ2-EB-III","December 2022","December 2024","December 2025","July 19, 2022",,"July 19, 2022",,,"https://ClinicalTrials.gov/show/NCT05464381"
71,"NCT03406585","Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes",,"Completed","No Results Available","Type1 Diabetes Mellitus","Drug: ProTrans: Allogeneic transplantation with WJMSCs|Drug: Placebos","Safety; measured through set safety parameters|Efficacy; comparison of the intervention versus placebo at day 372 versus start of treatment|Number of patients insulin independent (ADA criteria) at days 187 and 372|Number of patients with daily insulin needs <0.25U/kg at days 187 and 372|Insulin requirement/kg BW at days 187 and 372|HbA1c at days 187 and 372.|Glucose variability at day 372|Delta change of levels of fasting C-peptide at day 372|Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372","NextCell Pharma Ab","All","18 Years to 40 Years   (Adult)","Phase 1|Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ProTrans-T1D|2017-002766-50","November 28, 2017","July 1, 2020","September 4, 2020","January 23, 2018",,"January 11, 2022","Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03406585"
72,"NCT02336230","A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)",,"Completed","Has Results","Grade B aGVHD|Grade C aGVHD|Grade D aGVHD","Drug: remestemcel-L","Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy|Overall Survival (OS) Rate at Day 100 Post Initiation of Therapy|OS Rate at Day 100 Post Initiation of Therapy, Stratified by Responder Status at Day 28|OS Rate at Day 100 Post Initiation of Therapy, Stratified by Baseline aGVHD Grade|OS Rate at Day 100 Post Initiation of Therapy, Stratified by Organ Involvement|OR Rate at Day 56 and 100 Post Initiation of Therapy","Mesoblast, Inc.|Quintiles, Inc.|Mesoblast, Ltd.","All","2 Months to 17 Years   (Child)","Phase 3","55","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSB-GVHD001","June 4, 2015","April 9, 2018","April 9, 2018","January 12, 2015","March 17, 2022","March 17, 2022","Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|University of California at San Francisco, San Francisco, California, United States|Children's Hospital Colorado Center for Cancer/Blood Disorders, Aurora, Colorado, United States|Alfred I. DuPont Hospital for Children of the Nemours Foundation, Wilmington, Delaware, United States|Miami Children's Research Institute, Miami, Florida, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Albert Einstein College of Medicine, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oregon University, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Transplant Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Fred Hutchinson Cancer Research, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02336230/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02336230"
73,"NCT04711200","LYell SYndrome MEsenchymal Stromal Cells Treatment","LYSYME","Not yet recruiting","No Results Available","Epidermal Necrolysis|Lyell Syndrome|Toxic Epidermal Necrolysis|Overlap Syndrome|Mesenchymal Stromal Cells|Adipose Derived Stromal Cells","Drug: Adipose derived stromal cells intravenously injected","Safety : Observation of at least one adverse effect|Efficacy : Rate of complete or almost complete reepithelialisation|Rate of observed and predicted death by the SCORTEN|Duration of hospitalisation according to our historical cohort related to BSA involved|Duration of hospitalisation according to our historical cohort related to onset of the disease|Duration of hospitalisation according to our historical cohort related to SCORTEN|Duration of each mucous membranes healing ie.(buccal, nasal, genital, eyes)|Rate of sepsis|Rate of intensive care transfer|Rate of sequelae|Th1/Th2 immune response in the peripheral blood of the patients|Evaluation of expression profile of Th1/Th2 associated chemokines and anti-inflammatory chemokines in the peripheral blood|Epidermal chimerism study on healed skin biopsy|Cutaneous re-epithelialization rate at D5, D10 and D15 post-infusion according to the percentage of cutaneous BSA re-epithelialized in comparison to maximal cutaneous detachable-detached BSA observed.","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P150941J","September 2022","September 2025","September 2025","January 15, 2021",,"May 3, 2022",,,"https://ClinicalTrials.gov/show/NCT04711200"
74,"NCT04869397","Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells","ProTrans19+","Recruiting","No Results Available","Covid19","Biological: Allogeneic Wharton's jelly-MSCs (WJ-MSC)|Other: Placebo","Composite endpoint|Clinical status evaluation assessed by the 9-point ordinal scale|Survival|Time to clinical improvement assessed by the 9-point ordinal scale|Duration of hospitalization and ICU stay","McGill University Health Centre/Research Institute of the McGill University Health Centre","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2021-6954","June 14, 2021","June 30, 2022","July 30, 2022","May 3, 2021",,"June 15, 2021","McGill University Health Centre, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04869397"
75,"NCT00260338","Stem Cell Therapy for Vasculogenesis in Patients With Severe Myocardial Ischemia",,"Completed","No Results Available","Myocardial Ischemia|Coronary Heart Disease","Biological: stem cell","Improvement in myocardial perfusion measured by SPECT|Safety|Improvement in myocardial perfusion and function measured by PET and MR|Exercise time|Clinical angina status","Rigshospitalet, Denmark","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Jens Kastrup","December 2005","July 2009","July 2009","December 1, 2005",,"May 31, 2013","Cardiovascular Lab. 2014, The Heart Centre, Rigshospitalet, Blegdamcvej 9, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT00260338"
76,"NCT04333368","Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS","STROMA-CoV2","Completed","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2|Severe Acute Respiratory Distress Syndrome","Biological: Umbilical cord Wharton's jelly-derived human|Other: NaCl 0.9%","Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group|Lung injury score|Oxygenation index|In-hospital mortality|Mortality|Ventilator-free days|Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 > 200 (out of a prone positioning session)|Cumulative use of sedatives|Cumulative duration of use of sedatives|Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)|Cumulative use of neuromuscular blocking agents (other than used for intubation)|ICU-acquired weakness and delirium|Treatment-induced toxicity rate and adverse events up to day 28|Quality of life at one year (EQ5D-3L quality of life questionnaire)|Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level|Anti-HLA antibodies plasmatic dosage","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","47","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","APHP200395|2020-001287-28","April 6, 2020","October 26, 2021","October 26, 2021","April 3, 2020",,"February 18, 2022","Hôpital Pitié-Salpêtrière - APHP, Paris, France|Hôpital Européen Georges Pompidou - APHP, Paris, France",,"https://ClinicalTrials.gov/show/NCT04333368"
77,"NCT03233074","Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors","COSMOS","Recruiting","No Results Available","Myelodysplastic Syndromes|Acute Myeloid Leukemia|Cardio-vascular Surgery","Other: Bone marrow analyses","Changes in cellular properties of mesenchymal stromal cells|Number of differential biomarkers in mesenchymal stromal cells","Centre Hospitalier Universitaire de Saint Etienne|Institut de Cancérologie de la Loire","All","50 Years to 80 Years   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2017-0701|2017-A02088-45","November 17, 2017","September 30, 2022","September 30, 2022","July 28, 2017",,"February 8, 2022","CHU de Saint-Etienne, Saint-Priest-en-Jarez, France|CHU de Saint-Etienne, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT03233074"
78,"NCT03673748","Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells","MSV_LE","Not yet recruiting","No Results Available","Lupus Nephritis|Lupus Erythematosus","Drug: Mesenchymal stromal cells (MSC)|Drug: Placebo","Frequency of severe adverse events|Evolution of Complete Renal Response defined as decrease of urine protein:creatinine ratio (UPCR; Normal value<50mg/mmol)|Change in disease activity measured by change of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K)|Change in prednisone dose measured as percent of the baseline value|Cellular markers of inflammation and autoimmunity|Serum markers of inflammation and autoimmunity","Red de Terapia Celular|Hospital del Río Hortega|Hospital Clínico Universitario de Valladolid|University of Valladolid","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","36","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TerCel_006|2017-000391-28","December 2022","December 2023","June 2024","September 17, 2018",,"June 7, 2022","University Hospital Río Hortega, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT03673748"
79,"NCT03504241","Tolerance by Engaging Antigen During Cellular Homeostasis","TEACH","Recruiting","No Results Available","Kidney Transplantation|Renal Transplantation|Renal Transplant Recipient","Biological: Donor-derived Mesenchymal Stromal Cells|Drug: alemtuzumab|Drug: belatacept|Drug: sirolimus|Drug: mycophenolate mofetil|Drug: mycophenolate acid|Drug: prednisone","Proportion of Participants who Achieve Operational Tolerance|Proportion of Participants who Remain Off Immunosuppression|Proportion of Participants who Return to Immunosuppression|Proportion of Participants who Achieve Belatacept Monotherapy|Proportion of Participants who Die|Time from Transplant to the First Episode of Rejection|Incidence of Participants who Develop Donor Specific Antibody (DSA)|Incidence of Adverse Events Attributable to Mesenchymal Stromal Cells (MSC) Administration|Frequency of Select Adverse Events (AEs)|Incidence of Post-Transplant Diabetes|Frequency of Antibody-Mediated Acute Cellular Rejection|Frequency of Antibody-Mediated Chronic Rejection","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|PPD|Rho Federal Systems Division, Inc.","All","19 Years and older   (Adult, Older Adult)","Phase 1","6","NIH|Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAIT ITN062ST|UM1AI109565|NIAID CRMS ID#: 20676","July 30, 2018","December 2027","December 2029","April 20, 2018",,"May 13, 2022","Duke University Health System, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03504241"
80,"NCT05433298","Mesenchymal Stromal Cells for the Treatment of Patients With COVID-19.",,"Recruiting","No Results Available","COVID-19 Pneumonia|COVID-19","Biological: Mesenchymal stem cell|Other: Placebo","Safety of intravenously infused UCT-MSC suspension|Pulmonary function test to evaluate the improvement of respiratory function|Radiography to evaluate the improvement of respiratory function|6-minute walk to evaluate the improvement of respiratory function|Decrease on days of non-invasive mechanical ventilation|Biochemical tests to evaluate the improvement of laboratory parameters|Blood count to evaluate the improvement of laboratory parameters|Viral load to evaluate the improvement of laboratory parameters|Cytokine dosage to evaluate inflammatory parameters|Decrease in hospital stay|Computed tomography score to evaluate the improvement of pulmonary function|Reduction in the percentage of intubated patients|Decrease in mortality","Paulo Brofman|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Pontifícia Universidade Católica do Paraná","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","MSC SARS-CoV-2|U1111-1267-1200|31935420.7.1001.0020","May 1, 2022","November 26, 2022","December 31, 2022","June 27, 2022",,"June 27, 2022","Paulo Roberto Slud Brofman, Curitiba, Paraná, Brazil",,"https://ClinicalTrials.gov/show/NCT05433298"
81,"NCT04896853","Treatment of Respiratory Complications Associated With COVID-19 Infection Using ProTrans®",,"Recruiting","No Results Available","COVID-19 Acute Respiratory Distress Syndrome","Biological: ProTrans®","Safety and tolerance of a single infusion of ProTrans®|Effect of ProTrans® -MSC on patient clinical status, including mortality|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 7|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 15|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 30|Time to clinical improvement after ProTrans® - MSC infusion|Effect of of ProTrans® -MSC on lung damage|Duration of hospitalization and Intensive Care Unit (ICU) stay|Kinetics of COVID-19 viral load after ProTrans® -MSC infusion","NextCell Pharma Ab|Karolinska Trial Alliance","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","9","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO TRANS 19+|2020-002078-29","May 18, 2021","September 30, 2024","December 31, 2024","May 21, 2021",,"May 21, 2021","Department of Cardiology, Respiratory medicine and Physiology, Örebro University Hospital, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT04896853"
82,"NCT05283317","Effect of Mesenchymal Stromal Cells on Sepsis and Septic Shock",,"Completed","No Results Available","Sepsis|Septic Shock","Biological: Mesenchymal stem cells","Mortality|Length of stay in the hospital","TC Erciyes University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Mesenchymal Stromal Cells","March 11, 2018","August 25, 2019","November 13, 2019","March 16, 2022",,"March 16, 2022","Erciyes University, Kayseri, Turkey",,"https://ClinicalTrials.gov/show/NCT05283317"
83,"NCT04435249","ENgineered Tissue Repair of BronchopleUral fiSTula","ENTRUST","Not yet recruiting","No Results Available","Bronchopleural Fistula","Other: BPF-001","Safety: Emergent or worsening Serious Adverse Events (SAEs) related to the BPF implant during the 3 months post-defect repair|Efficacy: Bronchopleural Fistula (BPF) closure at 3 months assessed by visual appearance and no clinical signs of leaks.|Change from Baseline in Physiological and Quality of Life scores at 3, 6, 9, 12 months, Evaluation Questionnaire 5D (EQ-5D), 6-minute walking test (6MWT), ambulatory oxygen (O2).|Safety and tolerability: - Adverse Events (AEs) including pre-defined postoperative AEs of special interest up to 30± 3 days post implantation- Related AEs reported after 3, 6, 9, 12, 24 and 36 months|Viability and the integrity of the repair area (closure) visually via bronchoscope. Integrity assessed by visual appearance of no visible leaks- Structural closure of the defect and visual health of the defect area and surrounding tissue|Absence of other surgical interventions at 6, 9, 12, 24 and 36 months","Videregen Limited|Cell Therapy Catapult|Papworth Hospital NHS Foundation Trust|Royal Free Hospital NHS Foundation Trust","All","18 Years to 64 Years   (Adult)","Phase 1|Phase 2","5","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UK-2019-004939-24","October 2022","March 2024","November 2026","June 17, 2020",,"April 5, 2022",,,"https://ClinicalTrials.gov/show/NCT04435249"
84,"NCT05095532","Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT",,"Recruiting","No Results Available","Chronic Pancreatitis|Mesenchymal Stem Cells","Biological: Bone marrow-derived mesenchymal stem cells|Other: Placebo","Change in Islet Cell Function|Change in HbA1C levels from baseline to 12 months.|Proportion of insulin-independent patients following IAT|Average daily insulin requirement|Beta cell function as assessed by beta-score","Medical University of South Carolina|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Phase 1","42","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Pro00099487|R01DK126454","December 1, 2021","June 30, 2026","June 30, 2026","October 27, 2021",,"March 25, 2022","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT05095532"
85,"NCT02351011","Human Autologous MSCs for the Treatment of Mid to Late Stage Knee OA",,"Completed","No Results Available","Osteoarthritis of Knee","Biological: 1 x 10^6 MSCs|Biological: 10 x 10^6 MSCs|Biological: 50 x 10^6 MSCs","Safety as determined by the occurrence of local and systemic adverse events and/or serious adverse events.|Knee Injury and Osteoarthritis Outcome Score (KOOS)|Marx Activity Scale (Patient-reported activity)|Short-Form 36 (Health-related quality of life)|Whole Organ MRI Score (WORMS), Gadolinium-enhanced MRI, T2 Mapping (To assess joint structure, inflammation, and cartilage status over time)|Cartilage oligomeric matrix protein (COMP)|Hyaluronic acid (HA)|C-terminal telopeptide of type II collagen (CTXII)|Types I and II collagen cleavage (C1,2C)|Type II collagen cleavage (C2C)|IL-6/TNFα/IL-15","Jas Chahal|University Health Network, Toronto","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","MSC-001","February 2015","December 2018","December 2018","January 30, 2015",,"September 27, 2019","Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02351011"
86,"NCT04815213","The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans",,"Recruiting","No Results Available","Premature Ovarian Failure","Biological: expanded autologous bone marrow derived MSC","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Number of patients with enhanced hormonal profile, ovarian changes and endometrial changes|Number of patients with positive ovarian changes|Number of patients with increased endometrial thickness","University of Jordan","Female","18 Years to 38 Years   (Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","POF.UJCTC","January 1, 2020","January 31, 2022","January 31, 2022","March 24, 2021",,"March 24, 2021","Cell Therapy Center, University of Jordan, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04815213"
87,"NCT02165904","Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in SCI",,"Completed","Has Results","Spinal Cord Injury","Biological: Adult Autologous Mesenchymal Bone Marrow Cell","Efficacy-Sensivity Improvement Using the ASIA Score|Efficacy- Changes in Functional Independence Measure Scale|Efficacy-Change in Barthel Score|Efficacy-IANC-SCIFRS Scale|Efficacy-Changes in PENN Score.|Changes in ASHWORTH Score|Efficacy-Changes in EVA Score|Efficacy- Changes in Geffner Score|Efficacy- Changes in NBD Score|Efficacy-Changes in the Neurophysiological Parameters (SSEPs, Somatosensory Evoked Potentials)|Efficacy-Urodynammic in Terms of Detrusor Pressure|Efficacy-Urodynamic Studies Bladder Compliance|Efficacy-Urodynamic Studies Maximum Cystometric Capacity|Efficacy-modification of Magnetic Resonance Imaging (MRI)|Number of Adverse Events .|Efficacy- Expression of Neurotrophins in CSF (CerebroSpinal Fluid) Samples","Puerta de Hierro University Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CME-LEM2|2011-005684-24","May 2014","May 2016","May 2016","June 18, 2014","July 19, 2019","July 19, 2019","Hospital Puerta de Hierro, Majadahonda, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02165904"
88,"NCT03007576","Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)",,"Completed","No Results Available","Osteoarthritis,Knee","Biological: RegStem","Safety of RegStem by incidence of adverse events and changes in physical examinations, vital signs and the results of clinical lab tests.|Clinical assessment of International Knee Documentation Committee (IKDC) score|Clinical assessment of Knee injury and Osteoarthritis Outcome Score (KOOS)|Clinical assessment of visual analogue scale (VAS)|Clinical assessment of knee X-ray|Clinical assessment of knee MRI","EMO Biomedicine Corporation|Far Eastern Memorial Hospital","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 1","12","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EMOCT01","August 1, 2017","August 31, 2019","August 31, 2019","January 2, 2017",,"November 13, 2019","Far Eastern Memorial Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03007576"
89,"NCT04290182","A Study of Local Administration of Autologous Mesenchymal Stromal Cells in Dysphonic Patients With Vocal Fold Scarring",,"Recruiting","No Results Available","Hoarseness|Dysphonia|Aphonia|Vocal Fold; Scar","Biological: MSC-KI-PL-204","Safety and tolerability of treatment|Assessment of VF function|Assessment of subjective voice ratings|Assessment of tissue metabolism and healing","Karolinska University Hospital|Swedish Foundation for Strategic Research","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-06160 and 5.1-2019-92069","March 2020","June 2022","June 2023","February 28, 2020",,"February 28, 2020","Karolinska Trial Alliance, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04290182"
90,"NCT04744116","Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease",,"Recruiting","No Results Available","Hematopoietic and Lymphoid Cell Neoplasm|Steroid Refractory Graft Versus Host Disease","Other: Cellular Therapy|Drug: Ruxolitinib","Death from any cause|Response|Incidence of adverse events|Graft versus host disease status|Proportion of response|Time to complete response|Time to very good partial response|Time to partial response|Incidence of complete response for each organ|Incidence of very good partial response for each organ|Incidence of partial response for each organ|Durability of organ response|Cumulative incidence of non-relapse mortality (NRM)|Cumulative incidence of relapse/progression of the primary disease|Overall survival|Disease-free survival|Graft versus host disease-free survival|Incidence of chronic graft versus host disease|Incidence of systemic infections|Incidence of toxicities|Incidence of any grade cytokine release|Incidence of any infusional toxicity","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Early Phase 1","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-1122|NCI-2020-13889|P01CA148600","February 17, 2021","November 30, 2022","November 30, 2022","February 8, 2021",,"July 12, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04744116"
91,"NCT04629833","Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy","IDUNN","Recruiting","No Results Available","Steroid-refractory Acute Graft-versus-host Disease","Biological: MC0518|Biological: BAT","Overall Response (OR)|Freedom from Treatment Failure (FFTF)|Overall Survival|Acute Graft-versus-host Disease (aGvHD) Response|Change from Baseline in aGvHD Grades|Time to Response|Duration of Response|Best Overall Response (OR)|Cumulative Dose of Steroids for SR-aGvHD per Kilogram (kg) of Body Weight|Number of Participants with Chronic Graft-versus-host Disease (cGvHD)|Time to Chronic Graft-versus-host Disease (cGvHD)|Number of Participants with Graft Failure (GF)|Number of Participants with Relapse or Progression in Participants with Underlying Malignant Disease|Time to Relapse or Progression in Participants with Underlying Malignant Disease|Event-free survival (EFS)|Non-relapse Mortality (NRM)|Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs)|Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs) by Severity|Change from Baseline in Performance score based on Karnofsky scale (recipient age >= 16 years)|Change from Baseline in Performance score based on Lansky Scale|Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Health Status Index (HSI)|Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Visual Analogue Scale (VAS)|Change from Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) Score","medac GmbH","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC-MSC.1/aGvHD","August 16, 2021","January 28, 2024","December 31, 2025","November 16, 2020",,"June 8, 2022","CHU de Grenoble Hopital Albert Michallon, Grenoble, France|CHRU Lille- Hopital Claude Huriez, Lille, France|CHU de Nice Hopital Archet 1, Nice, France|Centre Hospitalier Lyon Sud Pavillon Marcel Berard 1G, Pierre Benite Cedex, France|Rennes, Rennes, France|Centre Hospitalier Universitaire CHU de Toulouse, Toulouse, France|Hopitaux De Brabois, Vandoeuvre les Nancy, France|Klinikum rechts der Isar, Munich, Bavaria, Germany|Universitaetsklinikum Wuerzburg - Medizinische Klinik und Poliklinik II - Zentrum fuer Allogene Blutstammzelltransplantation, Würzburg, Bavaria, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet - Frankfurt am Main, Frankfurt am Main, Hessen, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitatsklinikum Muenster, Münster, Nordrhein-Westfalen, Germany|Universitaet Duisburg-Essen - Universitaetsklinikum Essen - Klinik fuer Knochenmarktransplantation (KMT), Essen, North Rhine-Westphalia, Germany|Uniklinik Koeln, Koeln, North Rhine-Westphalia, Germany|Universitatsklinikum Carl Gustav Carus Dresden, Dresden, Sachsen, Germany|Selbststandige Abteilung fur Hamatologie und Internistische Onkologie, Leipzig, Saxony, Germany|Universitaetsklinikum Jena, Jena, Thüringen, Germany|Universitatsklinikum Jena, Jena, Thüringen, Germany|Charit Universitaetsmedizin Berlin, Berlin, Germany|University Hospital Bonn, Medizinische Klinik III, Bonn, Germany|Universitaetsklinikum Essen, Essen, Germany|Klinikum der Johann Wolfgang Goethe, Frankfurt, Germany|Universitatklinikum Freiburg, Freiburg, Germany|University Medical Center Mainz, Mainz, Germany|UniversitÃ¤tsklinikum Mannheim, Mannheim, Germany|University Hospital Tuebingen Medical Center, Tuebingen, Germany|Department of Pediatric Hematology, Oncology and BMT, Wroclaw Medical University, Wrocław, Dolnoslaskie, Poland|Hospital Universitario Vall dHebron, Barcelona, Spain|Barcelona, Barcelona, Spain|Institut Catal dOncologia, Barcelona, Spain|Barcelona, Barcelona, Spain|Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Puerta De Hierro, Madrid, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Center for Allogeneic Stem Cell Transplantation and Cell Therapy (CAST), Karolinska Universitetssjukhuset Huddinge, Huddinge, Sweden",,"https://ClinicalTrials.gov/show/NCT04629833"
92,"NCT05131412","Mesenchymal Stem Cells for the Treatment of Pneumonia Post Haematopoietic Stem Cell Transplantation","MSCTPHSCT","Completed","No Results Available","Pneumonia|Hematopoietic Stem Cell Transplantation",,"overall cure rate|time to cure","Guangzhou Women and Children's Medical Center","All","1 Year to 17 Years   (Child)",,"107","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GWCMC_HJ_XY_001","August 8, 2018","January 1, 2021","October 31, 2021","November 23, 2021",,"December 3, 2021","Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05131412"
93,"NCT02838069","A Study Evaluating the Efficacy of a Single Injection Autologous Adipose Derived Mesenchymal Stromal Cells in Patients With Knee Osteoarthritis","ADIPOA-2","Active, not recruiting","No Results Available","Osteoarthritis","Biological: Injection (2x106 ASC/5ml).|Biological: Injection (10x106 ASC/5ml).|Other: Placebo","Improvement of pain or physical function|Disability (WOMAC)|Disability (KOOS)|Disability (SAS)|Change in Quality of life|painkillers consumption|Structural changes (X-Ray)|Structural changes (MRI)","University Hospital, Montpellier|University Hospital, Toulouse|Assistance Publique - Hôpitaux de Paris|NATIONAL UNIVERSITY OF IRELAND, GALWAY (NUIG)|ISTITUTO ORTOPEDICO RIZZOLI (IOR)|Etablissement Français du Sang|Institut National de la Santé Et de la Recherche Médicale, France|ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN)|HUMAN MED AG (HM)|Stichting Katholieke Universiteit|SPORTS SURGERY CLINIC LIMITED|UNIVERSITA DEGLI STUDI DI PADOVA (UNIPD)|EVANGELISCHES WALDKRANKENHAUS SPANDAU KRANKENHAUSBETRIEBS GGMBH (EWK)|PINTAIL LTD (PT)|Centre National de la Recherche Scientifique, France|UNIVERSITAET ULM (UULM)|Cambridge University Hospitals NHS Foundation Trust|Aries srl (ARIES)","All","45 Years to 75 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UF 9494","September 20, 2016","March 2023","March 2024","July 20, 2016",,"July 11, 2022","UH Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02838069"
94,"NCT04466007","Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stem Cells in Diabetic Patients With Critical Limb Ischemia",,"Recruiting","No Results Available","Limb Ischemia|Diabetic Foot","Drug: High dose allogeneic mesenchymal stromal cells|Drug: Low dose allogeneic mesenchymal stromal cells|Drug: Placebos","Complication rate after treatment administration|Evaluation of vascularization though RMN|Rutherford-Becker scale|Wifi scale|Ankle arm index|Temperature|Twin perimeter|Neuropathic symptoms (altered sensitivity)|% amputations","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Universitario La Paz|Gregorio Marañón Hospital|Hospital Clínico Universitario de Valladolid|Hospital Universitario Virgen de la Arrixaca|University of Salamanca|Hospital General Universitario de Alicante|Hospital Universitario La Fe|Hospital Victoria Eugenia Cruz Roja Española","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NOMA (No More Amputations)","January 11, 2021","September 2022","September 2022","July 10, 2020",,"August 30, 2022","Hospital General de Alicante, Alicante, Spain|Hospital Gregorio Marañon, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|La Paz University Hospital, Madrid, Spain|Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Victoria Eugenia Cruz Roja Española, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital de Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04466007"
95,"NCT02033525","Mesenchymal Stromal Cells for Degenerative Meniscus Injury",,"Completed","No Results Available","Chronic Meniscal Injury","Drug: XCEL-M-ALPHA and standard rehabilitation|Other: Rehabilitation","VAS for pain|Safety|Efficacy by MRI|Efficacy by clinical questionnaires","Banc de Sang i Teixits|Hospital Universitari Quirón Dexeus|Ministerio de Sanidad, Servicios Sociales e Igualdad","All","40 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","XCEL-MEN-01|2011-006270-13","January 31, 2014","May 2, 2017","May 2, 2017","January 10, 2014",,"January 9, 2018","ICATME-Hospital Quiron Dexeus, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02033525"
96,"NCT03015623","A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy",,"Active, not recruiting","No Results Available","Acute Kidney Injury","Biological: SBI-101|Device: Sham","Safety and tolerability as measured by incidence of IP-related serious adverse events","Sentien Biotechnologies, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SBI-101-01","June 20, 2017","December 2021","December 2021","January 10, 2017",,"March 16, 2021","Lehigh Valley Hospital, Allentown, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03015623"
97,"NCT04918706","Allogeneic MSC Treatment for Pulmonary Emphysema",,"Recruiting","No Results Available","Pulmonary Emphysema|Mesenchymal Stromal Cells","Genetic: Allogeneic MSC|Drug: Placebo","Difference in expression of CD31|The difference between MSC and placebo treatment in change in CO diffusion capacity|The differences in expression of Surfactant Protein-C expression by alveolar type II cells in lung tissue obtained from study patients treated with placebo or MSC.|The difference in immunostaining of various leukocytes in resected lung tissue, including T lymphocytes, B lymphocytes, macrophages and neutrophils obtained from study patients treated with placebo or MSC.|The difference in shear stress responses, expressed as % elongation of 100 cells, of isolated pMVECs ex vivo obtained from study patients treated with placebo or MSC.|The difference in endothelial microparticles concentration and concentration of immunological markers in blood samples from study patients treated with placebo or MSC.|The correlation between arterial pO2 or gas transfer value TLCO (measured as standard of care) and the outcome of the primary objective of the study for patients treated with MSC or placebo.","Leiden University Medical Center|Erasmus Medical Center|Amsterdam UMC, location VUmc","All","45 Years to 65 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HEP study","June 25, 2019","September 1, 2021","June 1, 2022","June 9, 2021",,"June 9, 2021","Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT04918706"
98,"NCT04445220","A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy",,"Active, not recruiting","No Results Available","COVID-19|Acute Kidney Injury|Sepsis","Biological: SBI-101","Safety and tolerability as measured by incidence of IP-related serious adverse events","Sentien Biotechnologies, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SBI-101-02","November 19, 2020","March 2022","September 2022","June 24, 2020",,"January 14, 2022","University of New Mexico School of Medicine, Albuquerque, New Mexico, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04445220"
99,"NCT04294290","Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder","TACT","Active, not recruiting","No Results Available","Autism Spectrum Disorder","Biological: hCT-MSC infusion","Safety of hCT-MSC infusion as measured by incidence of infusion reactions|Safety of hCT-MSC infusion as measured by severity of infusion reactions|Safety of hCT-MSC infusion as measured by incidence of product-related infections|Safety of hCT-MSC infusion as measured by severity of product-related infections|Safety of hCT-MSC infusion as measured by evidence of alloimmunization via anit-HLA antibodies|Safety of hCT-MSC infusion as measured by incidence of graft vs. host disease|Safety of hCT-MSC infusion as measured by severity of graft vs. host disease|Safety of hCT-MSC infusion as measured by incidence of unexpected adverse events|Safety of hCT-MSC infusion as measured by severity of unexpected adverse events|Change in PDD Behavior Inventory Autism Composite Score (PDDBI)|Change in mean of the Socialization Subscale and Communication Subscale standard scores on the Vineland Adaptive Behavior Scales (VABS-3)|Change in Clinical Global Impression Scale (CGI)|Change in Communicative Development Inventories (CDI-2)|Change in attention abilities as assess via eye-tracking|Change in brain activity as measured by EEG","Duke University|The Marcus Foundation","All","18 Months to 48 Months   (Child)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00104460","February 24, 2021","December 1, 2022","December 1, 2022","March 4, 2020",,"January 20, 2022","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04294290"
100,"NCT04210440","The Treatment of Initial Stage of Hip Osteonecrosis: the Core Decompression","NEC15","Completed","No Results Available","Hip Necrosis|Hip Injuries","Procedure: Core decompression procedure","Avoiding arthroplasty|Harris Hip Score","Dante Dallari, MD|Istituto Ortopedico Rizzoli","All","18 Years to 50 Years   (Adult)","Not Applicable","52","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0029170","March 1, 2003","March 1, 2011","March 1, 2012","December 24, 2019",,"December 24, 2019","Istituto Ortopedico Rizzli, Bologna, Italy",,"https://ClinicalTrials.gov/show/NCT04210440"
101,"NCT05333029","Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD",,"Not yet recruiting","No Results Available","Graft Versus Host Disease","Biological: Allogeneic mesenchymal stromal cells (MSCs)|Biological: Extracorporeal photopheresis (ECP)","Percent of participants with response to therapy|aGVHD severity per Blood and Marrow Transplant Clinical Trials Network Manual of Operations (BMT MOP).|aGVHD incidence|Safety as measured by number of adverse events attributed to MSC and ECP therapy|Safety as measured by severity of adverse events attributed to MSC and ECP therapy|Number of participants with non-relapse mortality (NRM)|Number of participants with relapse-related mortality|Average time to relapse|Chronic GVHD incidence|Overall Survival (OS)|Steroid dose decrease|Steroid discontinuation rate|Change in FACT-BMT (Functional Assesment of Cancer Therapy-Bone Marrow Transplant) survey score|Percent regulatory T cells (% Tregs)|CD4:CD8 ratio","Molly Gallogly|Case Comprehensive Cancer Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE1Z20","October 2022","June 2023","December 2023","April 18, 2022",,"July 26, 2022","University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05333029"
102,"NCT03298763","Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer","TACTICAL","Recruiting","No Results Available","Adenocarcinoma of Lung","Genetic: MSCTRAIL|Drug: Placebo","Determination of recommended Phase II dose (RP2D) of MSCTRAIL in combination of cisplatin and pemetrexed treatment (Phase 1)|Tumour response rate (Phase 2)|Frequency of adverse events (Phase 1 & 2)|Best Overall response (Phase 1&2)|Progression free survival (Phase 1 & 2)|Overall survival (Phase 2)","University College, London","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","46","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","UCL/14/0453","March 5, 2019","September 1, 2023","September 1, 2025","October 2, 2017",,"April 28, 2021","University College London Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03298763"
103,"NCT03473301","A Study of UCB and MSCs in Children With CP: ACCeNT-CP","ACCeNT-CP","Completed","Has Results","Cerebral Palsy","Biological: Infusion of allogeneic umbilical cord blood|Biological: Infusion of MSCs","Change in Gross Motor Function Measure (GMFM-66) in Excess of Expected Change|Number of Adverse Events","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","24 Months to 60 Months   (Child)","Phase 1|Phase 2","91","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro00089362","April 10, 2018","February 26, 2020","May 31, 2021","March 22, 2018","February 17, 2021","August 19, 2021","Duke University Medical Center, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03473301/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03473301"
104,"NCT04484077","hCT-MSC Infusion in Adults With Autism Spectrum Disorder","AIMs","Recruiting","No Results Available","Autism Spectrum Disorder|Autism","Biological: hCT-MSC","Incidence of infusion reactions|Incidence of product-related infections|Evidence of formation of anti-HLA antibodies|Incidence of graft vs. host disease|Incidence of unexpected adverse events, by severity and relation to study|The Vineland Adaptive Behavior Scale Interview, 3rd Edition, Comprehensive interview form|Social Responsiveness Scale, Second Edition (SRS-2)|Social Withdrawal Subscale of the Aberrant Behavior Checklist, Community Edition (ABC-C)|Pediatric Quality of Life Inventory General Core Scales|Pediatric Quality of Life Inventory Family Impact Measure|Pediatric Quality of Life Inventory General Core Scales - Adult Version","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","18 Years to 34 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO00104691","January 24, 2022","March 2023","June 2023","July 23, 2020",,"September 6, 2022","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04484077"
105,"NCT03635450","Study of hCT-MSC in Newborn Infants With Moderate or Severe HIE",,"Completed","No Results Available","Moderate to Severe Hypoxic-ischemic Encephalopathy","Biological: Infusion of hCT-MSC","Incidence of infusion reactions|Incidence of Infections post-infusion|Survival|Neurodevelopmental Assessments","Joanne Kurtzberg, MD|Duke Clinical and Translational Science Institute (CTSI), part of the NIH Clinical and Translational Science Awards (CTSA)|Duke University","All","0 Hours to 48 Hours   (Child)","Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00100253","December 27, 2018","July 28, 2019","December 28, 2020","August 17, 2018",,"March 22, 2021","Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03635450"
106,"NCT05008588","Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Sub-Acute Stroke Infarct",,"Not yet recruiting","No Results Available","Ischemic Stroke","Biological: Conditioned Medium|Biological: Umbilical Cord Mesenchymal Stem Cells|Procedure: Neurologic and Neutrophic Drugs","Change from baseline Brain-Derived Neutrophic Factor at one month, 3 months and 6 months after transplantation|Change from baseline Vascular endothelial growth factor at one month, 3 months and 6 months after transplantation|Change baseline Magnetic Resonance Imaging at 6 month after transplantation|The National Institute of Health Stroke Scale (NIHSS) Scoring|modified Rankin Scale (mRS)","PT. Prodia Stem Cell Indonesia","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT/STROKE/PSI/2021","September 2021","December 2021","January 2022","August 17, 2021",,"August 17, 2021","Gatot Soebroto Hospital, Jakarta Pusat, DKI Jakarta, Indonesia|PT Prodia StemCell Indonesia, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT05008588"
107,"NCT01606215","Stem Cells in Rapidly Evolving Active Multiple Sclerosis","STREAMS","Completed","No Results Available","Multiple Sclerosis","Drug: Mesenchymal stem cells|Drug: Placebo","Frequency, Timing and Severity of Adverse events in MSC and placebo groups as Assessed by CTCAE v4.0|Total number of GELs at weeks 4, 12 and 24 after MSC therapy|contrast enhancing lesions identified over months 1, 3 and 6 will be compared between treatment groups.|Comparison of contrast enhancing lesions between treatment periods|Combined unique MRI activity|Relapses|Progression of disability|Disease free patients|MSFC score|peripheral immune responses|Type 4 hypersensitivity reaction","Imperial College London","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","21","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRO1959|13HH0228","January 2013","August 2019","August 2019","May 25, 2012",,"August 9, 2019","Imperial College Healthcare NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01606215"
108,"NCT02181478","Intra-Osseous Co-Transplant of UCB and hMSC",,"Completed","No Results Available","Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndromes|Myelofibrosis|Relapsed Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Relapsed Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Lymphoid Malignancies|Chronic Myelogenous Leukemia","Drug: cyclophosphamide|Drug: fludarabine phosphate|Radiation: total-body irradiation|Drug: cyclosporine|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Procedure: mesenchymal stem cell transplantation","Number of patients with BM cellularity failure: Measure of feasibility|Number of patients with ANC failure without evidence of disease: Measure of feasibility|Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment: Measure of feasibility|Incidence of toxicities assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Rate of neutrophil recovery|Rate of platelet recovery|Median time of neutrophil recovery|Median time of platelet recovery","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","6","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE1Z14|NCI-2014-01316|P30CA043703","July 22, 2015","December 19, 2019","February 7, 2020","July 4, 2014",,"December 4, 2020","Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02181478"
109,"NCT03389919","Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT",,"Recruiting","No Results Available","Mesenchymal Stem Cell Transplantation","Biological: MSC administration (intraosseal)","Engraftment","National Research Center for Hematology, Russia","All","18 Years and older   (Adult, Older Adult)","Phase 3","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BM-MSC-01","January 1, 2017","December 31, 2020","December 31, 2022","January 4, 2018",,"January 4, 2018","BMT department, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03389919"
110,"NCT02195323","Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)",,"Completed","No Results Available","Chronic Kidney Disease","Biological: Intravenous injection","mass formation|Creatinin|GFR","Royan Institute","All","25 Years to 60 Years   (Adult)","Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Kidney-004","April 2014","December 2015","January 2016","July 21, 2014",,"January 5, 2016","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02195323"
111,"NCT02801890","Evaluation of Autologous Adipose Derived Mesenchymal Stromal Cells (AD-MSC) Transplantation in Ultra Filtration Failure (UFF)",,"Completed","No Results Available","Ultra Filtration Failure","Biological: Intravenous injection","Systemic infection|Hepatic failure|Renal failure|Ratio of 4-hour dialysate/plasma creatinine (D/P Cr).|Ratio of 4-hour dialysate/plasma urea (D/P urea )|Ratio of dialysate glucose concentrations (D/D glucose )|peritoneal membrane transport function|Glomerular filtration rate (GFR):","Royan Institute","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-kidney-006","August 2015","February 2017","March 2017","June 16, 2016",,"April 27, 2017","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02801890"
112,"NCT03356821","Perinatal Arterial Stroke Treated With Stromal Cells Intranasally","PASSIoN","Completed","No Results Available","Perinatal Arterial Ischemic Stroke|Neonatal Stroke","Biological: Mesenchymal Stem Cells","Incidence of adverse events related to intranasal MSC treatment (safety and tolerability) in the acute setting.|Incidence of adverse events related to intranasal MSC treatment (safety and tolerability) in the subacute/long-term setting","UMC Utrecht|ZonMw: The Netherlands Organisation for Health Research and Development|M.D. Anderson Cancer Center|The University of Texas Health Science Center at San Antonio","All","up to 10 Days   (Child)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL59265.000.16","February 11, 2020","July 27, 2021","July 27, 2021","November 29, 2017",,"October 7, 2021","Wilhelmina Childrens Hostpital/University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03356821"
113,"NCT04247945","Co-transplantation of MSC in the Setting of Allo-HSCT",,"Recruiting","No Results Available","Allogeneic Hematopoietic Stem Cell Transplantation","Biological: Cotransplant with MSCs","Survival Rate|Cumulative Incidence of Graft-versus Host Disease|Incidence of Systemic Infections|Mean Time to Engraftment|Transplant-Related Mortality|Rates of Relapse","Fujian Medical University","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MSC-SCT-03","February 1, 2020","December 1, 2023","December 1, 2025","January 30, 2020",,"January 30, 2020","Union Hospital,Fujian Medical University, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT04247945"
114,"NCT04545307","Transplantation of Allogeneic MSC in Patients With Pulp Necrosis and Chronic Apical Periodontitis","MSC","Completed","No Results Available","Pulp Necroses|Apical Periodontitis","Biological: Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis","Sings and Symptoms Absence|Root canal Narrowing|Elongation of the root|Sensitivity tests perception|Repair of the bone lesion produced by the apical periodontitis|Stability of bio ceramic cements used in the obturation of the access cavity|Evaluate blood circulation within the root canal","Universidad Central de Venezuela|Instituto Venezolano de Investigaciones Cientificas","All","6 Years to 16 Years   (Child)","Phase 2|Phase 3","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSCYPPNAP001","November 27, 2019","December 27, 2019","January 27, 2020","September 11, 2020",,"September 16, 2020","Unidad de Terapia Celular del Instituto de Investigaciones Científicas, San Antonio de los Altos, Miranda, Venezuela",,"https://ClinicalTrials.gov/show/NCT04545307"
115,"NCT00395200","Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS)","MSCIMS","Completed","No Results Available","Multiple Sclerosis","Procedure: MSC Treatment","Adverse events|Visual function (acuity and colour)|Visual evoked potential latency|Optic nerve Magnetisation Transfer Ratio|Retinal nerve fibre layer thickness (by optical coherence tomography)|Brain lesion Magnetisation Transfer Ratio|MRI brain T1 hypointensity load|Multiple Sclerosis Functional Composite Score|Expanded Kurtzke Disability Status Score","University of Cambridge|Cambridge University Hospitals NHS Foundation Trust|Medical Research Council","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MRCRG44871|REC Reference: 07/Q0108/104","July 2008","December 2010","December 2010","November 2, 2006",,"October 25, 2011","University of Cambridge Dept of Clinical Neurosciences, Cambridge, Cambridgeshire, United Kingdom|University College London Institute of Neurology, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00395200"
116,"NCT05491135","Hepatocyte Microbeads for Acute Liver Failure","HELP","Not yet recruiting","No Results Available","Acute Liver Failure","Biological: HMB002","Safety: Moderate to severe (including life threatening and death) adverse event occurrences due to product in 1st 52 weeks post procedure|Tolerability: assessed by the proportion of initiated infusion where >80% of the infusion is received by the patient.|Biological activity: Survival with native liver at 24 weeks post treatment.|Change in blood marker levels including haematological, biochemical and coagulation baseline to 52 weeks post treatment.|Change in Quality of life measures from baseline to week 52|Patient survival with native liver at 52 weeks post treatment|Patient survival with transplanted or native liver at 24 and 52 weeks post treatment.","King's College Hospital NHS Trust|Medical Research Council","All","up to 16 Years   (Child)","Phase 1|Phase 2","17","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3571|2019-000316-29","September 2022","November 2025","May 2026","August 8, 2022",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT05491135"
117,"NCT04723303","Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)",,"Recruiting","No Results Available","Polymyositis|Dermatomyositis","Drug: Umbilical Cord Lining Stem Cells","Number of Subjects with Dose Limiting Toxicity (DLT) that begins during or following ULSC infusion as assessed within 24 hours.","University of Florida|Restem, LLC.","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","22","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DM/PM V2.0|IRB201903442|OCR33722","October 6, 2021","April 20, 2023","April 20, 2023","January 25, 2021",,"April 20, 2022","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04723303"
118,"NCT02408432","Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines",,"Completed","No Results Available","Cardiomyopathy|Heart Failure","Other: Laboratory Biomarker Analysis|Other: Standard of Care|Drug: Mesenchymal Stem Cell Transplantation","Incidence of adverse events of intravenous injection of human mesenchymal stem cells (hMSCs) in patients with recent onset left ventricular systolic dysfunction from anthracyclines|Change in improvement in left ventricular systolic function by 7 points|Development of acute heart failure decompensation|Emergency center visits for heart failure|Need for new pacemaker/automatic implantable cardioverter defibrillator|New onset arrhythmias|Sudden cardiac death|Acute pulmonary edema|Asymptomatic decrease in left ventricular ejection fraction (LVEF) of > 10%|Heart failure admission|Progression free survival","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","7","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0519|NCI-2015-00969","January 11, 2016","December 8, 2021","December 8, 2021","April 3, 2015",,"May 17, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02408432"
119,"NCT03099239","hCT-MSCs for Children With Autism Spectrum Disorder (ASD)","hCT-MSCs","Completed","No Results Available","Autism|Autism Spectrum Disorder|ASD","Biological: hCT-MSC infusion","Incidence of Infusion reactions|Incidence of Infections","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","2 Years to 11 Years   (Child)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00079421","June 6, 2017","June 10, 2019","June 10, 2019","April 4, 2017",,"December 3, 2019","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03099239"
120,"NCT04007081","Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia",,"Completed","No Results Available","Xerostomia|Head and Neck Cancer","Procedure: Bone Marrow Aspiration|Diagnostic Test: Ultrasound Imaging of Salivary Glands|Other: Salivary Assay|Other: Quality of Life Instruments","Number of Participant's whose Marrow-Derived MSCs Can be Expanded in vitro to > 50 million cells within two weeks|Change in participant QoL: XeQOL|Change in participant QoL: MDADI|Change in participant QoL: VAS|Change in participant Salivary Function: Unstimulated|Change in participant Salivary Function: Stimulated|Change in participant Salivary Gland Size","University of Wisconsin, Madison","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","UW19009|2019-0497|SMPH/HUMAN ONCOLOGY/HUMAN ONCO|A533300|Protocol Version 7/24/2020","October 18, 2019","March 10, 2021","March 10, 2021","July 5, 2019",,"March 24, 2021","University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04007081"
121,"NCT01915927","Stem Cell Fistula Plug in Perianal Crohn's Disease","MSC-AFP","Completed","No Results Available","Perianal Crohn's Disease","Drug: MSC-AFP","To determine the safety and toxicity of using autologous MSC coated fistula plug in patients with fistulizing Crohn's Disease.|To assess in preliminary fashion the response of fistula healing induced by the GORE plug containing MSC","William A. Faubion, M.D.|Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-009716","July 2013","December 2019","December 2019","August 5, 2013",,"January 3, 2020","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01915927"
122,"NCT03651791","In Vivo Tracking of USPIO Labeled MSC in the Heart","USPIO-MSC","Completed","No Results Available","Ischemic Heart Disease","Combination Product: USPIO labeled MSC injection","MSC identification using MRI in-vivo on day 0|MSC identification using MRI in-vivo on day 1|MSC identification using MRI in-vivo on day 7|MSC identification using MRI in-vivo after 2 weeks|MSC identification using MRI in-vivo after 4 weeks|MSC identification using MRI in-vivo after 8 weeks|MSC identification using MRI in-vivo after 12 weeks|MSC identification using MRI in-vivo after 26 weeks|Cardiac pump function changes|CCS class|Seattle Angina Questionnaire|Weekly number of angina attacks|Weekly nitroglycerin consumption|Adverse events","Rigshospitalet, Denmark","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","USPIO-MSC1","May 2013","June 2014","October 2017","August 29, 2018",,"August 29, 2018",,,"https://ClinicalTrials.gov/show/NCT03651791"
123,"NCT02962661","Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines",,"Recruiting","No Results Available","Cardiomyopathy|Heart Failure|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm","Other: Best Practice|Other: Laboratory Biomarker Analysis|Drug: Mesenchymal Stem Cell Transplantation","Incidence of adverse events|Change in left ventricular ejection fraction (LVEF)|Change in improvement of left ventricular (LV) systolic function as assessed by LVEF|LV end-systolic and end-diastolic volumes as determined by contrast-enhanced 2-dimensional(D)/3D echography|Cardiac death|Re-hospitalization after heart failure|Aborted death from an automatic implantable cardioverter defibrillator (AICD) firing|Nonfatal myocardial infarction|Revascularization","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","72","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0835|NCI-2016-01921","July 18, 2020","July 30, 2023","July 30, 2023","November 11, 2016",,"September 2, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02962661"
124,"NCT04126603","Impact of Semaglutide on CD34+ EPC and Fat Derived MSC",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Semaglutide|Drug: Placebos","CD34+ Endothelial Progenitor Cell number|CD34+ Endothelial Progenitor Cell Migration against serum SDF1a gradient|Gene Expression of CD34+ Endothelial Progenitor Cell number|Gene Expression of Subcutaneous Adipose cell|Arterial Stiffness: Pulse Wave Velocity|Arterial Stiffness: Pulse Wave Analysis|Body Composition: BMI|Body Composition: Body Fat Percent|Hip to Waist Ratio|Biochemistry: HbA1c|Biochemistry: LDL over HDl Ratio","Sabyasachi Sen|George Washington University","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NCR191206","August 1, 2019","December 30, 2022","August 30, 2023","October 15, 2019",,"March 22, 2022","The GW Medical Faculty Associates, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT04126603"
125,"NCT01585857","ADIPOA - Clinical Study",,"Completed","No Results Available","Osteoarthritis","Biological: Autologous adipose derived stem cells administrated for intra-articular use","Recording of Serious Adverse Events|Functional status of the knee|Quality of life","University Hospital, Montpellier","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 1","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8606","April 2012","December 2014","December 2014","April 26, 2012",,"December 4, 2014","UH Montpellier, Montpellier, France|Orthopädische Klinik, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT01585857"
126,"NCT03909139","Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear",,"Recruiting","No Results Available","Acetabular Labrum Tear|Femoro Acetabular Impingement|Chondral Defect|Bone Marrow Aspirate Concentrate|Mesenchymal Stromal Cell","Biological: BMAC","Change iHOT--33 Surveys from preoperative to various postoperative timepoints|Change HOS Surveys from preoperative to various postoperative timepoints|Change NAHS Surveys from preoperative to various postoperative timepoints|Change LEFS Surveys from preoperative to various postoperative timepoints|Change mHHS Surveys from preoperative to various postoperative timepoints|Change RAND-36 Surveys from preoperative to various postoperative timepoints|Degree of Improvement on Hip VAS Pain Score|Patient Satisfaction Questionnaires","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019P002191","September 6, 2019","June 30, 2023","June 30, 2025","April 9, 2019",,"May 6, 2022","MGH, Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03909139"
127,"NCT05086939","Multicenter Clinical Trial Comparing Treatment With Allogeneic Mesenchymal Cells Versus Autologous Mesenchymal Cells and Versus Active Control With Hyaluronic Acid in Patients With Knee Osteoarthritis.","ARTROCELL","Recruiting","No Results Available","Knee Osteoarthritis","Drug: Autologous MSCs|Drug: Allogenic MSCs|Drug: Hyaluronic Acid","Range of motion.|Pain self-assessment.|Knee Osteoarthritis.|Functional response.|X-ray changes of osteoarthritis.|Radiological response using nuclear magnetic resonance imaging.|Perceived general well-being.|Feasibility assessment of a multicentre strategy production of both cell types with several Cell Production Units|Evaluation of presence of adverse events related with investigational medical product (IMP).","Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León|Instituto de Investigación Biomédica de Salamanca|Spanish Clinical Research Network - SCReN|Institut d'Investigacions Biomèdiques August Pi i Sunyer|Hospital Universitari de Bellvitge","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARTROCELL|2019-002446-21","May 26, 2021","December 2025","December 2025","October 21, 2021",,"June 2, 2022","Hospital Clinic, Barcelona, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Hospital Fundación Jiménez Díaz, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Complejo Asistencial Universitario de Salamanca, Salamanca, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT05086939"
128,"NCT02525432","Autologous Stem Cell Study for Adult TBI (Phase 2b)",,"Enrolling by invitation","No Results Available","Brain Injuries, Traumatic|Brain Injuries, Acute|TBI (Traumatic Brain Injury)","Biological: Placebo Infusion|Biological: Autologous BMMNC Infusion","Macro and micro structural properties of grey matter (GM) and white matter (WM) regions will measured using high-resolution anatomical MRI and diffusion tensorm imaging and comparisons made between groups.|Brain imaging measures of GM and WM structural integrity will be compared to functional and neurocognitive scores and comparisons made between groups.|Compare neuro-inflammatory biomarkers between groups..|Measure the number of participants with infusion related adverse events.|Measure spleen ultrasound size over time and corresponding changes in inflammatory cytokines.|Determine if microglial activation is associated with TBI and can be accurately measured with brain PET and DT-MRI imaging when compared to PET imaging data from healthy volunteers (enrolled under a different protocol).|Quantify the extent and location of microglial activation by brain PET imaging and how activity correlates with performance of neurocognitive outcomes measures.|Determine the extent to which an IV infusion of autologous BMMNC post-injury impacts microglial activation by brain PET imaging.","The University of Texas Health Science Center, Houston|United States Department of Defense|U.S. Army Medical Research and Development Command","All","18 Years to 55 Years   (Adult)","Phase 2","55","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-16-0283","November 21, 2016","August 2023","December 2023","August 17, 2015",,"August 2, 2022","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02525432"
129,"NCT03171194","Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus",,"Completed","No Results Available","System; Lupus Erythematosus","Drug: Low Dose Mesenchymal Stem Cells (MSCs)","Frequency of Grade 3 or higher adverse events|Frequency of All Adverse Events|Change in Disease Activity|Change in Patient Reported Outcomes - Life|Change in Patient Reported Outcomes - Fatigue|Change in Patient Reported Outcomes - Pain|Change in Patient Reported Outcomes - Depression|Change in Disease Biomarkers - Cellular|Change in Disease Biomarkers - Serum","Medical University of South Carolina","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00061632","April 27, 2017","April 30, 2018","October 25, 2018","May 31, 2017",,"May 2, 2019","Emory University, Atlanta, Georgia, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03171194"
130,"NCT02696876","Synovium Brushing to Augmented Microfracture for Improved Cartilage Repair","AURA","Recruiting","No Results Available","Defect of Articular Cartilage|Cartilage Injury|Osteoarthritis, Knee","Device: Arthroscopic synovial brushing|Procedure: Microfracture","The mean change in the number of MSCs present in the knee pre- and post- microfracture/microfracture plus arthroscopic synovial brushing.|Number of patients whose clinical effusion scores improve at 3, 6 and 12 months|Number of patients whose semi-quantitative MRI cartilage scores improve at 6 and 12 months|Median KOOS scores at 3, 6 and 12 months (pain; other symptoms; function in daily living; function in sport; knee-related QoL; average score)|Western Ontario and McMaster Universities Arthritis Index (WOMAC)|Visual Analogue Scale (VAS)","University of Leeds|The Leeds Teaching Hospitals NHS Trust","All","16 Years to 55 Years   (Child, Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RR15/173","January 2017","December 2021","December 2021","March 2, 2016",,"April 28, 2021","Chapel Allerton Orthopaedic Centre, Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02696876"
131,"NCT05060107","Intra-articular Injection of MSC-derived Exosomes in Knee Osteoarthritis (ExoOA-1)","ExoOA-1","Not yet recruiting","No Results Available","Osteoarthritis, Knee","Biological: Exosomes (sEVs)","Adverse Event|Incidence of injection-related pain according to VAS scale (0-100mm)|Incidence of injection-related sinovitis according to effusion grading scale of knee joint|Pain reduction|Disability reduction|Percentage of responders","Francisco Espinoza|Universidad de los Andes, Chile","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C4C060921","October 5, 2021","April 5, 2023","October 5, 2023","September 28, 2021",,"September 28, 2021",,,"https://ClinicalTrials.gov/show/NCT05060107"
132,"NCT05066334","Efficacy of Intradiscal Injection of Autologous BM-MSC in Subjects With Chronic LBP Due to Multilevel Lumbar IDD","DREAM","Recruiting","No Results Available","Intervertebral Disc Degeneration|Chronic Low-back Pain","Drug: Autologous BM-MSC|Procedure: Sham","Pain Change|Functional disability index evaluation|Disability evolution|Quality of life evolution|Drug consumption of rescue painkillers medication|Measurement of pain|Employment and work status assessment|Structural assessment|Evaluation of costs|Body Mass Index evaluation|Haematological evaluation: safety parameter|Coagulation status: safety parameter|Metabolic functions: safety parameter|Inflammation: safety parameter|Urinalysis|Spine examination|Specific Adverse Events Evaluation","Campus Bio-Medico University|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Center for Outcomes Research and Clinical Epidemiology, Italy","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","DREAM (GR - 2018-12367168)|2019-002749-40","March 22, 2021","May 31, 2022","June 9, 2023","October 4, 2021",,"October 4, 2021","Campus Bio-Medico University of Rome, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT05066334"
133,"NCT04759105","Efficacy of Intradiscal Injection of Autologous BM-MSC in Worker Patients Affected by Chronic LBP Due to Multilevel IDD","ACTIVE","Recruiting","No Results Available","Intervertebral Disc Degeneration|Chronic Low-back Pain","Drug: Autologous BM-MSC|Other: Sham Procedure","Pain clinical relief|Functional disability index improvement|Work ability improvement|Measure pain relief of the patient|Measure functional disability index of the patient|Evaluate disability and quality of life evolution of the patient|Disability and quality of life evolution|Assess rescue painkillers medication|Structural assessment|Evaluation of cost|Incidence of Adverse Events (AE)|Assessment of vital signs|Evaluation of blood and urine analysis|Analysis of chemical biomarkers for tissue degeneration","Campus Bio-Medico University|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Center for Outcomes Research and Clinical Epidemiology, Italy","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","ACTIVE trial_(BRIC2018-ID03)|2019-004476-19","November 17, 2020","July 31, 2021","June 30, 2022","February 18, 2021",,"February 18, 2021","Campus Bio-Medico University of Rome, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04759105"
134,"NCT01840540","MSC for Occlusive Disease of the Kidney",,"Completed","No Results Available","Atherosclerotic Renal Artery Stenosis|Ischemic Nephropathy|Renovascular Hypertension","Drug: Arterial infusion of autologous mesenchymal stem cells","Renal blood flow and function in the treated kidneys.|Level of kidney function.","Mayo Clinic","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-009298","April 2013","March 2014","April 2017","April 25, 2013",,"August 7, 2017","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01840540"
135,"NCT04390139","Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19","COVIDMES","Active, not recruiting","No Results Available","COVID-19|SARS-CoV 2|Adult Respiratory Distress Syndrome","Drug: XCEL-UMC-BETA|Other: Placebo","All-cause mortality at day 28|Safety of WJ-MSC|Need for treatment with rescue medication|Need and duration of mechanical ventilation|Ventilator free days|Evolution of PaO2 / FiO2 ratio|Evolution of the SOFA index|Evolution of the APACHE II score|Duration of hospitalization|Evolution of markers of immune response (leucocyte count, neutrophils)|Feasibility of WJ-MSC administration|Evolution of disease biomarker: polymerase chain reaction (RT-PCR)|Evolution of disease biomarker: lactate dehydrogenase (LDH)|Evolution of disease biomarker: D-dimer|Evolution of disease biomarker: Ferritin","Banc de Sang i Teixits","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BST-COVID-01","May 13, 2020","September 2022","December 2022","May 15, 2020",,"July 6, 2022","Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Mútua de Terrassa, Terrassa, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04390139"
136,"NCT04519671","Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease","PFCD","Recruiting","No Results Available","Perianal Crohn Disease|Perianal Fistula|Crohn Disease","Drug: Mesenchymal Stem Cells|Other: Placebo","Treatment related adverse events|Complete clinical healing","Amy Lightner|The Cleveland Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20-1020","November 19, 2020","November 2022","November 2022","August 20, 2020",,"April 5, 2022","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04519671"
137,"NCT02017912","Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS","NurOwn","Completed","No Results Available","Amyotrophic Lateral Sclerosis (ALS)","Biological: Autologous MSC-NTF cells|Biological: Placebo","Number of patients with adverse events|Change in Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale (ALS-FRS) slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation.|Change in SVC slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation","Brainstorm-Cell Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BCT-001-US","May 2014","March 2016","July 2016","December 23, 2013",,"July 18, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|UMass Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02017912"
138,"NCT05054803","Cell Therapy for Chronic Traumatic Cervical Incomplete Spinal Cord Injury",,"Active, not recruiting","No Results Available","Spinal Cord Injury Cervical","Drug: WJ-MSC (XCEL-UMC-BETA)|Drug: Placebo","Incidence of adverse events|American Spinal Injury Association (ASIA) impairment scale|Motor evoked potentials|Somatosensory evoked potentials|Electrical pain threshold perception|Handgrip Strength|Walking index for spinal cord injury (WISCI II)|Numerical scale for neuropathic pain assessment|Modified Ashworth scale for spasticity|Spinal Cord Independence Measure III (SCIM III)|World Health Organization Quality of life questionnaire (WHOQOL-BREF)|Psychological general well-being index (PGWBI)|Hospital Anxiety and Depression Scale (HADS)|Community Integration Questionaire (CIQ-IG)|AntiHLA antibodies in cerebrospinal fluid (CSF)|Detection of donor cells in CSF","Banc de Sang i Teixits|Institut Guttmann|Academic Research Organization (ARO) - VHIR|Complexo Hospitalario Universitario de A Coruña","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BST-SCI-02","October 13, 2021","October 2023","October 2025","September 23, 2021",,"July 8, 2022","Hospital de Neurorehabilitació Institut Guttmann, Badalona, Barcelona, Spain|Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain",,"https://ClinicalTrials.gov/show/NCT05054803"
139,"NCT03325322","Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease",,"Recruiting","No Results Available","Chronic Kidney Diseases|Diabetes Mellitus|Diabetic Nephropathies","Dietary Supplement: Fisetin|Drug: Placebo oral capsule","Change in inflammatory markers including C-reactive protein|Effect on Mesenchymal stem cell function including cell migration|Effect on measures of Frailty including Fried Criteria|Kidney function including estimated glomerular filtration rate|Kidney function including urine protein excretion rate|Number of participants with treatment-related adverse events including hospitalization","Mayo Clinic","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","16-010521","January 2, 2018","January 2023","April 2025","October 30, 2017",,"September 14, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03325322"
140,"NCT03555773","Micro-fragmented Adipose Tissue and Complex Crohns' Anal Fistulas",,"Completed","No Results Available","Crohn Disease|Perianal Fistula","Procedure: Lipogems","Healing|Health-related quality of life assessed by a disease specific questionnaire|Health-related quality of life assessed by a generic questionnaire","IRCCS Azienda Ospedaliero-Universitaria di Bologna","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Lipogems-crohn2","May 11, 2016","June 28, 2017","June 28, 2017","June 14, 2018",,"June 14, 2018","S. Orsola-Malpighi Hospital, Bologna, BO, Italy",,"https://ClinicalTrials.gov/show/NCT03555773"
141,"NCT01051882","Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: MSC-NTF cells transplantation (IM)|Biological: MSC-NTF cells transplantation (IT)","Safety evaluation and tolerability of a single treatment administration of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Safety evaluation and tolerability of single intrathecal injection (IT) into the cerebrospinal fluid (CSF) of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale (ALS-FRS)|Changes in muscle strength grading (MVIC) by muscle chart|Changes in forced vital capacity (FVC %) (In the progressive disease stage group only).|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Changes in upper and lower extremities circumference (cm)|Changes in EMG parameters|Need and time to tracheotomy or permanent assisted ventilation|Overall survival, calculating time to death","Brainstorm-Cell Therapeutics|Hadassah Medical Organization","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-NTF-001-HMO-CTIL","June 2011","December 2012","March 2013","January 20, 2010",,"January 10, 2019","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT01051882"
142,"NCT01144962","Dose-escalating Therapeutic Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease",,"Completed","No Results Available","Crohn's Disease|Fistula","Procedure: Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.|Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.","Safety and efficacy (fistula closure)|Clinical scores|Endoscopic scores|Quality of life|C-reactive protein (CRP)|Safety","Leiden University Medical Center|DigestScience","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P10.102","June 2010","September 2014","December 2014","June 16, 2010",,"December 30, 2014","Leiden University Medical Center (LUMC), Leiden, Zuid Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT01144962"
143,"NCT04869761","Stem Cell Therapy for Chronic Kidney Disease",,"Recruiting","No Results Available","Chronic Kidney Diseases|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Diabetes Mellitus|Diabetic Nephropathies","Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion|Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions","Adverse events and/or serious adverse events","LaTonya J. Hickson|Mayo Clinic","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","20-008380","October 7, 2021","December 2026","May 2027","May 3, 2021",,"November 4, 2021","Mayo Clinic Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04869761"
144,"NCT04961658","Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients","AMETHYST","Recruiting","No Results Available","Septic Shock","Biological: GEM00220","The safety of GEM00220 will be assessed by monitoring adverse events|Maximum Feasible Tolerated Dose","Northern Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT-GEM-001","August 11, 2021","September 2023","August 2024","July 14, 2021",,"June 21, 2022","Lakeridge Health, Oshawa, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04961658"
145,"NCT03102879","Encapsulated Mesenchymal Stem Cells for Dental Pulp Regeneration.","RanoKure","Completed","Has Results","Periapical Periodontitis","Procedure: Regenerative Endodontic Procedure|Procedure: Conventional Root Canal Treatment","Number of Participats Showing Efficacy (Functionality)|Change in Pulpal Response|Change in Apical Lesion Size|Pain to Percussion|Numbers of Participants With Adverse Event|Pulp Regeneration","Universidad de los Andes, Chile|Cells for Cells, Chile","All","16 Years to 58 Years   (Child, Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RPD-8-16","September 23, 2016","September 30, 2018","September 30, 2018","April 6, 2017","January 21, 2020","January 21, 2020","Universidad de los Andes, Santiago, Chile","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03102879/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03102879"
146,"NCT03840343","Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease",,"Recruiting","No Results Available","Diabetic Kidney Disease|Diabetic Nephropathies|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Chronic Kidney Disease|Diabetic Nephropathy Type 2|Kidney Failure|Kidney Insufficiency","Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose|Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose","Adverse Events|Kidney Function","Mayo Clinic|Regenerative Medicine Minnesota","All","45 Years to 75 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-002423|RMM 091718 CT 001","October 23, 2019","December 2024","December 2025","February 15, 2019",,"March 15, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03840343"
147,"NCT03874572","Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth","MESRIX-SAFETY","Active, not recruiting","No Results Available","Xerostomia Due to Radiotherapy|Hyposalivation|Xerostomia|Oropharynx Cancer|Salivary Gland Diseases|Dry Mouth|Mesenchymal Stem Cells|Mesenchymal Stromal Cells|Stem Cells","Biological: Allogeneic adipose derived stem/stromal cells","Safety: Number of patients with serious adverse events|Immune reponse :Development of donor specific antibodies|Efficacy: Change in Unstimulated Whole Salivary flow rate|Efficacy: Change in Stimulated Whole Salivary flow rate|Efficacy: Change in quality of life|Efficacy: Salivary gland function|Efficacy: Change in Saliva composition|Efficacy: Change in Saliva Proteomics|Efficacy: Change in RNA in Saliva|Immune reponse","Rigshospitalet, Denmark","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CVB2018-2|2018-003856-19","March 18, 2019","June 22, 2020","December 1, 2025","March 14, 2019",,"January 29, 2021","Department of Otolaryngology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark|Department of Otolaryngology, Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03874572"
148,"NCT04919135","Mesenchymal Stem/Stromal Cell Therapy in the Treatment of Frailty",,"Not yet recruiting","No Results Available","Frailty","Biological: Umbilical Cord Mesenchymal Stem Cells transplantation|Drug: standard frailty treatment and supplementary medication","Adverse events and serious adverse events|Reduced activities|Slowing of mobility|reduction of handgrip strength|exhaustion|the level of pain in the knee|respiratory function|Quality of Life|patients' inflammation|patients' immune|immunoregulatory properties of umbilical cord-derived mesenchymal stem/stromal cells|Cellular senescence|metabolic profiles of CD3+ cells","Vinmec Research Institute of Stem Cell and Gene Technology","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","VinmecISC2111","July 1, 2021","November 30, 2021","November 30, 2022","June 9, 2021",,"June 9, 2021",,,"https://ClinicalTrials.gov/show/NCT04919135"
149,"NCT03876197","Mesenchymal Stem Cells for Radiation-induced Xerostomia",,"Enrolling by invitation","No Results Available","Radiation Toxicity|Xerostomia Due to Radiotherapy|Dry Mouth|Hyposalivation|Mesenchymal Stem Cells|Mesenchymal Stromal Cells|Long Term Adverse Effects","Biological: Autologous adipose-derived mesenchymal stem/stromal cells|Other: Placebo","Safety: Serious Adverse Events (SAEs) and new chronic diseases|Overall survival|Relapse of oropharyngeal cancer|New malignancies|Zoonotic Diseases|Patient-reported outcome measures-Health-related quality of life (HRQoL","Rigshospitalet, Denmark","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","CVB2019-1|2014-004349-29","August 1, 2020","December 1, 2022","December 1, 2023","March 15, 2019",,"October 22, 2020","Department of Otolaryngology, University Hospital of Copenhagen, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03876197"
150,"NCT00186914","Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation",,"Completed","No Results Available","Osteodysplasia","Biological: Marrow stromal cell infusion","To evaluate the safety of the stromal cell infusion","St. Jude Children's Research Hospital|Drexel University|Wayne State University","All","Child, Adult, Older Adult","Phase 1","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STOD","July 1999","November 2001","January 2008","September 16, 2005",,"March 4, 2015","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00186914"
151,"NCT03920397","Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation","Pancreatic β-cell function after an adipose tissue-derived stem/stromal cells infusion|Glycemic control after an adipose tissue-derived stem/stromal cells|Oral cholecalciferol 2000UI/day supplementation","Universidade Federal do Rio de Janeiro","All","16 Years to 35 Years   (Child, Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Nutro_MesenchymalStemCells_DM1","March 1, 2015","March 1, 2021","May 1, 2021","April 18, 2019",,"May 26, 2021","Clementino Fraga Filho University Hospital of Rio de Janeiro, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT03920397"
152,"NCT03905824","The Effectiveness of Adding Allogenic Stem Cells After Traditional Treatment of Osteochondral Lesions of the Talus","OLT","Recruiting","No Results Available","Osteochondral Fracture of Talus","Biological: Allogenic stromal mesenchymal cells derived from the umbilical cord|Procedure: Debridement and microfracture","Change on tissue reparation quality|Change over time of general health status|Change over time of functional limitations of foot and ankle.|Change over time of functionality of musculoskeletal ankle and foot pathology|Change on declared pain|Surgical time|Complication rate|Cost-effective comparative analysis","University of Chile","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","OLT Protocol","January 15, 2019","December 31, 2020","December 31, 2024","April 5, 2019",,"April 9, 2019","Universidad de Chile Clinical Hospital, Santiago, Independencia, Chile",,"https://ClinicalTrials.gov/show/NCT03905824"
153,"NCT04821479","Repeated Mesenchymal Stem Cell Injections in ALS",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: Mesenchymal stem cells (MSC)","Safety of multiple intrathecal MSC administration. Incidence of adverse events following multiple intrathecal MSC injections during 2 years follow-up period|Effect of repeated intrathecal MSC injections on the progression rate (monthly changes) of ALSFRSr|Effect of repeated intrathecal MSC injections on the progression rate (monthly changes) of respiratory forced vital capacity FVC","Hadassah Medical Organization","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0208-16-HMO","January 1, 2016","June 30, 2020","December 31, 2020","March 29, 2021",,"March 29, 2021",,,"https://ClinicalTrials.gov/show/NCT04821479"
154,"NCT05280002","Adipose-tissue-derived Total-Stromal-cells (TOST) Therapy in Knee Osteoarthritis",,"Completed","No Results Available","Osteoarthritis Knees","Biological: Adipose Tissue derived Total-Stromal-Cells (TOST)","Changes in pain intensity|Changes in Physical functioning of knee joints.|Changes in femoral cartilage thickness","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|Dhaka Medical College","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","BSMMU/2018/25","January 1, 2018","October 31, 2021","December 31, 2021","March 15, 2022",,"March 15, 2022","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",,"https://ClinicalTrials.gov/show/NCT05280002"
155,"NCT01777646","Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF","Safety evaluation and tolerability of a single treatment administration in an escalating-dose of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale|Changes in muscle strength grading (MVIC) by muscle chart|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Change in upper and lower extremities circumference (cm)|Changes in EMG parameters","Brainstorm-Cell Therapeutics|Hadassah Medical Organization","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","14","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-NTF-002-HMO-CTIL","December 2012","September 2014","September 2015","January 29, 2013",,"March 8, 2018","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT01777646"
156,"NCT02467387","A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure",,"Completed","Has Results","Non-Ischemic Heart Failure","Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Drug: Lactated Ringer's Solution","Safety Will be Evaluated by Number of AE|Change in LVEF From Baseline to Day 90 Post-initial Infusion.","CardioCell LLC|Stemedica Cell Technologies, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STEM-104-M-CHF","June 1, 2014","May 11, 2017","May 11, 2017","June 10, 2015","January 7, 2020","January 7, 2020","MedStar Washington Hospital Center, Washington, District of Columbia, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwestern University Centers for Heart Failure Therapy, Chicago, Illinois, United States|Stony Brook Heart Institute, Stony Brook, New York, United States|Hospital of the University of Pennsylvania, Heart Failure and Transplant Program, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02467387/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02467387"
157,"NCT04433104","Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Chronic Obstructive Pulmonary Disease",,"Recruiting","No Results Available","COPD","Biological: Umbilical Cord Mesenchymal Stem Cells transplantation|Drug: drug therapy according to Vietnamese MOHS procedure","Adverse events and serious adverse events|Quality of Life using Georges Respiratory Questionnaire|Chest CT|arterial blood gas analysis (pH)|arterial blood gas analysis (PaO2)|arterial blood gas analysis (PaCO2)|arterial blood gas analysis (BE)|arterial blood gas analysis (HCO3-)|Respiratory functions (FEV1)|Respiratory functions (FEV1/FVC)|Respiratory functions (VC)|Respiratory functions (TLC)|Respiratory functions (RV)|Respiratory functions (DLCO)|Respiratory functions (DLNO/DLCO)|inflammatory response (CRP)|inflammatory response (Pro-BNP)|inflammatory response (Troponin-T)|cytokine analysis from patients' plasma|modified medical research council","Vinmec Research Institute of Stem Cell and Gene Technology","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","VinmecISC1916","June 9, 2020","July 30, 2021","December 25, 2021","June 16, 2020",,"April 21, 2021","Vinmec International Hospital Times City, Hà Nội, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT04433104"
158,"NCT02975960","ADMSCs for the Treatment of Systemic Sclerosis",,"Completed","No Results Available","Systemic Sclerosis","Biological: injection of autologous stromal vascular fraction","Change from baseline modified Rodnan Skin score (mRSS) of hands at 12 weeks|Change from baseline Raynaud's condition score at 12 weeks|Change from baseline Visual Analog Score for pain the hands at 12 weeks|Changes from baseline mRSS (total) at 12 weeks|Change from baseline Kapandji score at 12weeks|Change from baseline Cochin hand function scale at 12 weeks|Change from baseline Systemic sclerosis HAQ at 12 weeks|Change from baseline peripheral vasculature at 12 weeks|Change from baseline finger circumference at 12 weeks","The Catholic University of Korea|Seoul St. Mary's Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KC16TISI0343","October 25, 2016","October 30, 2017","January 20, 2018","November 29, 2016",,"January 25, 2018","Seoul St. Mary's hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02975960"
159,"NCT03726255","Stem Cell Therapy: a Compassionate Use Program in Perianal Fistula","RESCeCUF","Completed","No Results Available","Perianal Fistula","Procedure: Mesenchymal Stem Cell injection","Number of patients with fistula healed|Number of adversus events","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","All","24 Years to 70 Years   (Adult, Older Adult)",,"52","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","EO166-18_FJD","April 1, 2014","January 26, 2018","July 26, 2018","October 31, 2018",,"November 13, 2018","Instituto Investigación Sanitario Fundación Jiménez Díaz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03726255"
160,"NCT05305833","Stem Cells and Stromal Vascular Fraction for Temporomandibular Joint Disease",,"Recruiting","No Results Available","Temporomandibular Joint Disorders|Temporomandibular Disorder|Temporomandibular Joint Osteoarthritis|Temporomandibular Joint Pain|Temporomandibular Joint Effusion","Biological: Stem Cells","Change from Baseline Pain at 15th day|Change from baseline maximum mouth opening at 15th day|Change from baseline maximum mouth opening at 1 month|Change from baseline maximum mouth opening at 3 months|Change from baseline maximum mouth opening at 6 months|Change from baseline pain at 1 month|Change from baseline pain at 3 month|Change from baseline pain at 6 month|Change from baseline 'comfort ' at 6th month","TC Erciyes University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2021/584","October 1, 2021","December 1, 2022","December 1, 2023","March 31, 2022",,"March 31, 2022","Erciyes University, Kayseri, Turkey",,"https://ClinicalTrials.gov/show/NCT05305833"
161,"NCT03818737","Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)","MILES","Completed","No Results Available","Osteoarthritis","Biological: Bone Marrow Derived MSCs|Biological: Adipose-derived MSCs|Biological: Umbilical Cord Tissue (UCT) MSCs|Drug: Corticosteroid injection","Change in Visual Analog Pain Scale (VAS-pain) Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Pain Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Total Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Symptoms Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Activities of Daily Living (ADL) Function Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Sports and Recreation Function Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Quality of Life (QoL) Subscale Score|Change in EuroQuality of Life (EQ-5D-3L) Index Score|Change in Patient-Reported Outcomes Measurement Information System (PROMIS 29) Score","Emory University|The Marcus Foundation","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 3","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB00108046","March 28, 2019","May 31, 2022","May 31, 2022","January 28, 2019",,"July 8, 2022","Andrews Institute, Gulf Breeze, Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|Duke University, Durham, North Carolina, United States|Sanford Health, Fargo, North Dakota, United States|Sanford Health, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT03818737"
162,"NCT01468064","Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Ischemic Stroke","AMETIS","Completed","No Results Available","Stroke|Infarction, Middle Cerebral Artery","Genetic: Autologous BMSCs transplantation|Genetic: Autologous EPCs transplantation|Genetic: IV infusion of placebo","Number of adverse events after infusion of BMSCs or EPCs.|Changes in functional outcomes measured by the modified Rankin Scale (mRS) and the Barthel index (BI).","Southern Medical University, China|The Second People's Hospital of Nanhai District of Foshan|The First People's Hospital of Haizhu District Guangzhou|Cellonis Biotechnology Co. Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ZJH-001|2011A030400007","November 2011","December 2015","March 2017","November 9, 2011",,"April 2, 2021","Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01468064"
163,"NCT00781872","Mesenchymal Stem Cells for the Treatment of MS",,"Completed","No Results Available","Multiple Sclerosis","Biological: Injection of autologous bone marrow derived mesenchymal stem cells","Safety of one or multiple intrathecaland intravenous injections of autologous MSC in Multiple sclerosis|Clinical effects in terms of changes in the expended disability status scale (EDSS) at 3-6 month intervals|Immunological effects of treatment with MSC in MS","Hadassah Medical Organization","All","35 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MS22MSC-HMO-CTIL","October 2006","December 2009","December 2009","October 29, 2008",,"March 29, 2021",,,"https://ClinicalTrials.gov/show/NCT00781872"
164,"NCT04223622","Effects of ASC Secretome on Human Osteochondral Explants","ASC-OA","Recruiting","No Results Available","Osteoarthritis","Biological: ASC secretome","Validation of the cell-free approach based on the use of ASC secretome on an ex vivo OA model by evaluation of cell viability, histological features and gene/protein expression of cartilage and bone biomarkers","Istituto Ortopedico Galeazzi","All","18 Years and older   (Adult, Older Adult)",,"24","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","ASC-OA","April 12, 2021","December 2022","December 2022","January 10, 2020",,"December 3, 2021","IRCCS Istituto Ortopedico Galeazzi, Milano, MI, Italy",,"https://ClinicalTrials.gov/show/NCT04223622"
165,"NCT04340284","Adipose Tissue Derived Stromal Vascular Fraction (SVF) Application in Treatment of Long Bones Nonunion",,"Completed","No Results Available","Nonunion of Fracture","Biological: autologous adipose tissue derived stromal vascular fraction (SVF)","Union|Short Form 12 survey","Dr. Himanshu Bansal Foundation","All","25 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","11","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HimanshubansalFoundation","November 10, 2019","February 14, 2020","February 14, 2020","April 9, 2020",,"August 2, 2022","Anupam Hospital, Rudrapur, Uttrakhand, India",,"https://ClinicalTrials.gov/show/NCT04340284"
166,"NCT05484856","Evaluation of Clinical Efficacy of Autologous Adipose Tissue Derived ADSCSs in Treatment of Osteoarthritis (OA)",,"Completed","No Results Available","Osteoarthritis, Knee","Biological: Autologous adipose tissue derived stromal cells","changes in womac score|changes in cartilage thickness as assessed on 1.5 T MRI|changes in joint space width","Dr. Himanshu Bansal Foundation","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","140","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAH/CLINICALTRIAL/01/2016","May 16, 2016","June 27, 2020","February 25, 2021","August 2, 2022",,"August 2, 2022","Anupam Hospital, Rudrapur, Uttarakhand, India",,"https://ClinicalTrials.gov/show/NCT05484856"
